


ADVANCEMENTS IN CARDIOVASCULAR RESEARCH AND THERAPEUTICS: MOLECULAR AND NUTRACEUTICAL PERSPECTIVES



Editors:

V. V. Sathibabu Uddandrao
Parim Brahma Naidu

Bentham Books

Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives

Edited by

V. V. Sathibabu Uddandrao

Department of Biochemistry

K.S. Rangasamy College of Arts and Science (Autonomous)

Tiruchengode-637215

Tamilnadu, India

&

Parim Brahma Naidu

ICMR-National Animal Resource Facility

for Biomedical Research (NARFBR)

Hyderabad-500078

Telangana, India

Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives

Editors: V. V. Sathibabu Uddandrao and Parim Brahma Naidu

ISBN (Online): 978-981-5050-83-7

ISBN (Print): 978-981-5050-84-4

ISBN (Paperback): 978-981-5050-85-1

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2022.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 CARDIOVASCULAR DISEASES AND NUTRACEUTICALS: UNDERLYING MECHANISM AND THERAPEUTIC BIOMARKERS	1
<i>Pallavi Saxena, Vinod Kumar, Noopur Khare, Neeraj Pal, Dibyabhaba Pradhan Pradeep K Chaturvedi, Arun Kumar Jain, Manoj Kumar, V. V. Sathibabu Uddandrao and Umesh Kumar</i>	
1. INTRODUCTION	2
1.1. Cardiovascular Disorders	2
1.2. Cardiovascular Diseases Burden: Global and National	2
1.3. Potential Risk Factors for CVD	4
1.4. Therapies in Use for CVD Treatment	6
1.4.1. ACE Inhibitors	6
1.4.2. Angiotension II Receptor Blockers	6
1.4.3. Antiarrhythmics	6
1.4.4. Antiplatelet Drugs	8
1.4.5. M. Anti-coagulants Drugs	8
1.4.6. Diuretics	9
2. NUTRACEUTICALS AND CARDIOVASCULAR HEALTH	10
2.1. Nutraceuticals	10
2.2. Potential Nutraceuticals	10
2.2.1. Plant Sterols/ Stanols	11
2.2.2. Cruciferous Vegetables	11
2.2.3. Garlic	12
2.2.4. CoQ10	12
2.2.5. Turmeric	12
2.2.6. Grape Skin	12
2.2.7. Fish Oil/Olive Oil	13
2.2.8. Vegetables	13
2.2.9. Carnitine	13
2.2.10. Berberine	13
2.2.11. Flavonoids	14
2.2.12. Prebiotics	14
2.2.13. Probiotics	14
2.2.14. Protein and Protein Peptides	14
2.2.15. Vitamins	15
3. NUTRACEUTICALS MODULATE GENETIC EXPRESSION	16
3.1. NF- κ B Regulatory Network	16
3.2. Nrf2 Regulates Antioxidant and Detoxification Genes	16
4. BIOINFORMATICS APPLICATION IN NUTRACEUTICALS AND CVD PREVENTION	17
4.1. Identification of New Therapeutic Biomarkers	18
CONCLUSION	18
CONSENT FOR PUBLICATION	19
CONFLICT OF INTEREST	19
ACKNOWLEDGEMENTS	19
REFERENCES	19

CHAPTER 2 CONGESTIVE HEART FAILURE: INSIGHT ON PHARMACOTHERAPY	25
<i>Sri Bharathi G.S, Sakthi Sundaram S, Prabhakaran S, Lalitha V, Haja Sherief S</i>	
<i>Duraisami R and Sengottuvelu S</i>	
1. INTRODUCTION	26
1.1. Hypertrophic Cardiomyopathy (HCM)	27
1.2. Left Ventricular Noncompaction (LVNC)	27
1.3. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)	27
1.4. Restrictive Cardiomyopathy (RCM)	27
2. PREVALENCE	28
3. PATHOPHYSIOLOGY	29
4. DRUG THERAPY	29
4.1. Diuretics	29
4.2. Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)	29
4.3. Beta-adrenergic Blocking Agents (Beta Blockers)	30
4.4. Vasopressin Receptor Antagonists	30
5. MANAGEMENT OF HEART FAILURE	30
5.1. Acute Decompensation	30
5.2. Chronic Management	30
5.3. Palliative Care	31
5.4. Cardiac Glycosides	31
5.4.1. Chemistry of Cardiac Glycosides	31
5.4.2. Sources of Cardiac Glycosides	32
5.4.3. Mechanism of Cardiac Glycosides	33
5.4.4. Pharmacological Activity of Cardiac Glycosides	33
6. DIGOXIN	34
7. TOXICOKINETICS	34
CONCLUSION	35
CONSENT FOR PUBLICATION	35
CONFLICT OF INTEREST	35
ACKNOWLEDGEMENTS	35
REFERENCES	35
CHAPTER 3 DIET, INFLAMMATION AND CARDIOVASCULAR DISORDERS	38
<i>M Kesavan and HV Manjunathachar</i>	
1. INTRODUCTION	38
1.1. Diet Induced Inflammation	38
1.2. Dietary Inflammatory Index (DII)	39
2. DIFFERENT PATTERNS OF DIET AND THEIR CHARACTERISTICS	39
2.1. The Zone Diet	40
2.2. Ketogenic Diet	40
2.3. Mediterranean Diet	40
2.4. DASH (Dietary Approaches to Stop Hypertension) Diet	41
2.5. The Paleo Diet	41
2.6. Vegan and Vegetarian Diet	42
3. CARDIOVASCULAR DISEASES (CVD), PRO AND ANTI-INFLAMMATORY AGENTS	42
4. SPICES	45
CONCLUSION	47
CONSENT FOR PUBLICATION	47
CONFLICT OF INTEREST	47
ACKNOWLEDGEMENTS	47

REFERENCES	47
CHAPTER 4 RODENT AND NON-RODENT ANIMAL MODELS FOR CARDIOVASCULAR DISEASES	52
<i>Irfan Ahmad Mir, HV Manjunathachar, R Ravindar Naik, SSSYH Qadri and Taniya Saleem</i>	
1. RODENT MODELS FOR CVD	53
2. ATHEROSCLEROSIS AND DIABETIC MODELS	53
2.1. LDLR ^{-/-} Mice	54
2.2. ApoE ^{-/-} Mice	55
2.3. SR-BI KO Mice	56
2.4. db/db Mouse	56
2.5. Ob/ob Mice	57
2.6. Zucker Fatty Rat	57
2.7. Zucker Diabetic Fatty (ZDF) Rat	58
2.8. Otsuka Long–Evans Tokushima fatty (OLETF) Rats	58
2.9. Goto-Kakizaki (GK) Rats	59
2.10. WNIN/GR-Ob Rat	59
3. HEART FAILURE MODELS	61
3.1. Myocardial Ischemia-Induced Heart Failure	62
3.2. Pressure Overload Models	62
3.3. Chemical-induced Cardiomyopathy Models	62
4. NON-RODENT MODELS OF CARDIO-VASCULAR DISEASES	63
4.1. Overview of Advantages and Disadvantages of Non-rodent Animal Models	63
4.2. Pigs	64
4.3. Atherosclerotic Disease Models	66
4.4. Pig Models for Stent Application	68
4.5. Pig Models of Infarction and Heart Failure	68
4.6. Dogs	70
4.7. Sheep	71
CONCLUSION	72
CONSENT FOR PUBLICATION	72
CONFLICT OF INTEREST	72
ACKNOWLEDGEMENTS	72
REFERENCES	73
CHAPTER 5 APPLICATION OF 21ST CENTURY GENETIC ENGINEERING TOOLS AND CRISPR-CAS9 TECHNOLOGIES TO TREAT MOST ADVANCED CARDIOVASCULAR DISEASES OF HUMANS	79
<i>J. Venkateshwara Rao, R. Ravindar Naik, S. Venkanna and N. Ramesh Kumar</i>	
1. INTRODUCTION	80
2. THE CRISPR/CAS9 PROTEIN TECHNOLOGY	82
3. APPLICATION OF CRISPR/CAS9 TECHNOLOGY AS A THERAPEUTIC TOOL FOR HUMAN DISEASES	83
3.1. Cystic Fibrosis (CF)	83
3.2. Sickle Cell Anemia	84
3.3. Thalassemia	85
3.4. Huntington’s Disease	85
3.5. Duchenne Muscular Dystrophy	86
3.6. Hemophilia	86
3.7. Chronic Granulomatous Disorders (CGD)	87
4. MULTIFACTORIAL DISEASES	87

4.1. Cancer	88
4.2. Cardiovascular Diseases (CVD)	88
5. APPLICATIONS OF CRISPR/CAS9 IN CARDIAC RESEARCH	89
5.1. Gene Therapy for CVD	90
5.2. The Future of CRISPR/Cas9 Genome Editing in Cardiac Research	92
6. CHALLENGES OF APPLICATION OF CRISPR/CAS9	93
6.1. Delivery Systems of CRISPR/Cas9	93
6.2. Off-target Effects	94
6.3. Ethical Issues	94
6.4. Emerging CRISPR Technologies	95
CONCLUSION	96
CONSENT FOR PUBLICATION	96
CONFLICT OF INTEREST	96
ACKNOWLEDGEMENTS	97
REFERENCES	97

CHAPTER 6 ROLE OF VYANA VAYU IN CARDIOVASCULAR SYSTEM, ETIOPATHOGENESIS AND THERAPEUTIC STRATEGIES: AN AYURVEDA PERSPECTIVE	104
<i>Savitri Vasudev Baikampady, C. S. Hiremath, Reeta Varyani and Venketesh</i>	
1. INTRODUCTION	104
2. A PREAMBLE TO VATA	106
2.1. Vyana Vayu	106
2.1.1. Role of Vyana Vayu in the Heart	107
2.1.2. Role of Vyana Vayu in Vasculature (Dhamani and Sira)	108
2.1.3. Role of Vyana Vayu in Skeletal Muscles and other Organs	108
3. ETIOLOGY	109
4. PATHOGENESES	112
4.1. Stage of Accumulation (Sanchaya)	112
4.2. Stage of Aggravation (Prakopa)	112
4.3. Stage of Dissemination (Prasar)	113
4.4. Stage of Localization (Sthanasamshraya)	113
4.5. Stage of Manifestation (Vyakta)	114
4.6. Stage of Complication (Bheda)	114
5. CONCOMITANT CONCEPT	115
6. CLINICAL IMPLICATIONS	116
7. TREATMENT STRATEGIES	117
7.1. Diet	117
7.2. Exercise	118
7.3. Pharmacological Approach	118
7.3.1. Terminalia Arjuna (TA)	118
7.3.2. Innula Recemosa	118
7.3.3. Fagonia Arabica	118
8. OMICS STUDY AND AYURVEDIC THERAPEUTIC STRATEGIES	118
CONCLUSION	119
10. HIGHLIGHTS	119
CONSENT FOR PUBLICATION	120
CONFLICT OF INTEREST	120
ACKNOWLEDGEMENTS	120
REFERENCES	120

CHAPTER 7 NUTRACEUTICALS: THE POTENTIAL AGENTS TO RESCUE HUMAN RACE FROM CARDIOVASCULAR DISEASES (CVDS)	125
<i>Sreedevi Gandham, Ghali. EN.Hanuma Kumar and Balaji Meriga</i>	
1. INTRODUCTION	125
2. CVDS: PATHOPHYSIOLOGY	127
3. CVDS: TREATMENT OPTIONS	129
4. PLANTS AND HERBS FOR TREATMENT OF CVDS	134
4.1. Polyphenols	136
4.2. Flavonoids	136
4.3. Carotenoids	136
4.4. Other Phytochemicals	137
4.5. Vitamins	137
5. NUTRACEUTICALS TO TREAT CVDS	137
6. SPICES AS EFFECTIVE NUTRACEUTICALS TO TREAT CVDS	138
6.1. Ginger (Zingiber Officinale)	138
6.2. Turmeric (Curcuma Longa)	139
6.3. Black pepper (Piper Nigrum)	140
6.4. Coriander (Coriandrum Sativum)	141
6.5. Cinnamon (Cinnamomum Zeylanicum)	142
6.6. Garlic (Allium Sativum)	143
6.7. Cloves (Syzygium Aromaticum)	144
6.8. Other Common Spices	145
7. NUTRACEUTICALS/SPICES: MODE OF ACTION	147
CONCLUSION	148
CONSENT FOR PUBLICATION	148
CONFLICT OF INTEREST	148
ACKNOWLEDGEMENTS	148
REFERENCES	148
CHAPTER 8 AMELIORATIVE POTENTIAL OF BIOCHANIN-A AGAINST DEXAMETHASONE INDUCED HYPERTENSION THROUGH MODULATION OF RELATIVE MRNA AND PROTEIN EXPRESSIONS IN EXPERIMENTAL RATS	156
<i>V. V. Sathibabu Uddandrao, P. P. Sethumathi, Parim Brahma Naidu, S. Vadivukkarasi, Mustapha Sabana Begum and G. Saravanan</i>	
1. INTRODUCTION	157
2. MATERIALS AND METHODS	157
2.1. Chemicals	157
2.2. Animals	158
2.3. Induction of Hypertension	158
2.4. Experimental Design	158
2.5. Measurement of Body Weight	158
2.6. Indirect Measurement of Blood Pressure in Conscious Rats	158
2.7. Hemodynamic and Vascular Responsiveness Measurements	159
2.8. Assay of Nitric Oxide Metabolites	159
2.9. Assay of Superoxide Production	159
2.10. RT-PCR Analysis	159
2.11. Western Blot Analysis	160
2.12. Statistical Analysis	161
3. RESULTS	161
4. DISCUSSION	165
CONCLUSION	168

CONSENT FOR PUBLICATION	168
CONFLICT OF INTEREST	168
ACKNOWLEDGEMENTS	168
REFERENCES	168
CHAPTER 9 ZINGIBERENE, AN ACTIVE CONSTITUENT FROM ZINGIBER OFFICINALE AMELIORATED HIGH-FAT DIET-INDUCED OBESITY CARDIOMYOPATHY IN RATS	171
<i>S. Jaikumar, G. Somasundaram and S. Sengottuvelu</i>	
1. INTRODUCTION	171
2. MATERIALS AND METHODS	173
2.1. Chemicals	173
2.2. Animals	173
2.3. HFD Composition	173
2.4. Experimental Design	173
2.5. Measurement of Body Weight, Anthropometrical and Morphological Parameters	174
2.6. Estimation of Biochemical Markers	174
2.7. Determination of Cardiac Lipid Profile	174
2.8. Assessment of Oxidative Stress Markers in Heart	174
2.9. Statistical Analysis	174
3. RESULTS	175
3.1. Effect of ZB on Anthropometrical and Morphological Parameters	175
3.2. Influence of ZB on Diabetic Markers	176
3.3. Effect of ZB on Cardiac Lipid Profiles	177
3.4. ZB Ameliorated Oxidative Stress in Heart	178
4. DISCUSSION	179
CONCLUSION	182
CONSENT FOR PUBLICATION	182
CONFLICT OF INTEREST	182
ACKNOWLEDGEMENTS	183
REFERENCES	183
CHAPTER 10 BETAINES, A NUTRACEUTICAL AMELIORATED MYOCARDIAL INFARCTION BY ATTENUATION OF PRO-INFLAMMATORY CYTOKINES AND MATRIX METALLOPROTEINASE PRODUCTION IN RATS	186
<i>G. Somasundaram, S. Jaikumar and S. Sengottuvelu</i>	
1. INTRODUCTION	187
2. MATERIALS AND METHODS	188
2.1. Animals	188
2.2. Experimental Design	188
2.3. Measurement of Heart Weight and the Ratio of Heart Weight to Body Weight	189
2.4. Assessment of Cardiac Diagnostic Markers	189
2.5. Estimation of Serum Inflammatory Markers	189
2.6. Determination of Serum Matrix Metalloproteinases	189
2.7. RT-PCR Analysis	189
2.8. Statistical Analysis	190
3. RESULTS	190
4. DISCUSSION	194
CONCLUSION	197
CONSENT FOR PUBLICATION	197
CONFLICT OF INTEREST	197
ACKNOWLEDGEMENTS	197

REFERENCES	197
SUBJECT INDEX	203

FOREWORD

I was delighted when I received a request from Dr. P. Brahmanaidu and Dr. V. V. Sathibabu Uddandrao to write a brief foreword to the reprint of this book because, for many years, I have admired their incredible contribution to research especially in the field of metabolic disorders and nutraceuticals. I was excited when they started writing a book on “Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives” and I would be first in line to buy it. In fact, editors sent me a copy of the book draft and I was humbled. Not only was this a great book, but it was also a great way to write and construct chapters.

Looking through this magnificent volume, I am absolutely amazed by the way they presented this book about the pathophysiology of cardiovascular disorders and their novel treatment approaches by nutraceuticals. It is more than a book of lovely illustrations and a mine of information, demonstrating therapeutic approaches and it is a source of inspiration and information in the field of cardiovascular pharmacology. This book is unique and surely a work of treasure for anyone who is interested in cardiovascular research. So, I strongly recommend you to read it, enjoy it and learn from it.

Dr. Ramachandra Subbaraya Gudde
ICMR- National Animal Resource
Facility for Biomedical Research (NARFBR)
Hyderabad, Telangana,
India- 500078

PREFACE

Cardiovascular diseases (CVD) belong to the most severe health problems and are considered the main cause of morbidity and mortality in modern society. CVDs consist of a broad spectrum of diseases, including atherosclerosis, hypertension, myocardial ischemia, cardiomyopathy, and heart failure. Risk factors for CVDs include hypertension, hyperlipidemia, obesity, diabetes mellitus, metabolic syndrome, and a sedentary lifestyle. Therapeutic effects against CVD have been demonstrated by several medicinal plants and nutraceuticals thus presenting new possibilities for the treatment of CVD risk. Evidence suggests that this approach is very promising. So, the aim of this book is to present an update on the most recent evidence related to the use of nutraceuticals in the context of the prevention and treatment of CVD.

Chapter 1 discusses CVD and nutraceuticals and the underlying mechanism and therapeutic biomarkers. The chapter presents the beneficial effects of nutraceuticals on the heart and also gives an insight into the bioinformatics approach to identify novel therapeutic biomarkers in order to update the practitioner's awareness of the use of nutraceuticals for CVD management. Chapter 2 provides detail about congestive heart failure and insight into pharmacotherapy. This chapter explains possible pharmaceutical approaches to treat congestive heart failure. Chapter 3 provides a review of diet, inflammation, and CVDs. The chapter reveals the role of diet in the prevention of vascular inflammation and the usefulness of antioxidants in preventing CVD. Chapter 4 represents the applications, advantages and disadvantages of various rodent and non-rodent animal models in the research on CVD especially while evaluating nutraceuticals' effects against CVD. On the other hand, chapter 5 discusses the CRISPR-cas9 technologies in the 21st century and their applications in cardiovascular diseases.

Chapter 6 discloses the role of Indian Ayurvedic approaches to the cardiovascular system, etiopathogenesis, and therapeutic strategies. The chapter highlights the precipitants that attenuate Vyana Vayu and addresses curative measures to restore Vyana Vayu. Chapter 7 depicts nutraceuticals as potential agents to rescue the human race from CVD. The chapter points out the current scenario of CVD, pathophysiology, therapeutic drugs available, the role of nutraceuticals in treating CVD, and their mode of action with a special emphasis on commonly used kitchen spices. Chapter 8 explains the therapeutic potential and mode of action of Biochanin-A, a natural compound predominantly found in soy, chickpea, peanuts, alfalfa sprouts, and red clover against hypertension in experimental rats. Chapter 9 concentrates on the ameliorative potential of Zingiberene, a monocyclic sesquiterpene that is the principal constituent of ginger (*Zingiber officinale*) against obesity and cardiomyopathy. Finally, chapter 10 presents the amelioration of myocardial infarction through the attenuation of pro-inflammatory cytokines and matrix metalloproteinase production by Betaine, a well-known nutraceutical widely occurring in plants, animals and rich dietary sources.

Dr. V. V. Sathibabu Uddandrao
Assistant Professor
Department of Biochemistry
K.S. Rangasamy College of Arts and Science
Tiruchengode-637215
Tamilnadu, India

Dr. Parim Brahma Naidu
DST-Inspire Faculty
ICMR-National Animal Resource Facility
for Biomedical Research (NARFBR)
Hyderabad-500078
Telangana, India

List of Contributors

Arun Kumar Jain	ICMR- National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, 110029, India
Balaji Meriga	Department of Biochemistry, Sri Venkateswara University, Tirupati, Andhrapradesh, India
C. S. Hiremath	Department of Cardiology, Sri Sathya Sai Institute of Higher Medical Sciences, EPIP Area, Whitefield, Bangalore, India
Dibyabhaba Pradhan	ICMR AIIMS Computational Genomics Centre, New Delhi, 110029, India
Duraisami R	Department of Pharmacognosy, Nandha College of Pharmacy, Erode Tamilnadu, India
Ghali. EN.Hanuma Kumar	Department of Biochemistry, Sri Venkateswara University, Tirupati, Andhrapradesh, India
G. Saravanan	Department of Biochemistry, Centre for Biological Sciences, K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Namakkal District, Tamilnadu, 637215-India
G. Somasundaram	Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502-India
Haja Sherief S	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India
HV Manjunathachar	CMR- National Animal Resource Facility for Biomedical Research, Genome Valley, Hyderabad,Telangana-500101, India
Irfan Ahmad Mir	ICMR-National Animal Resource Facility for Biomedical Research, Genome Valley, Hyderabad,Telangana-500101, India
J. Venkateshwara Rao	Department of Zoology, Osmania University, Hyderabad, Telangana, India
Lalitha V	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India
M Kesavan	Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh-243 122, India
Manoj Kumar	Biochemistry Department Ghaziabad, Narinder Mohan Hospital and Heart Center, Uttar Pradesh, 201007, India
Mustapha Sabana Begum	Department of Biochemistry, Muthayammal College of Arts and Science, Rasipuram, Namakkal, Tamil Nadu 637408, India
Neeraj Pal	GB Pant University of Agriculture and Technology, Pantnagar, Uttarakhand-263145, India
NoopurKhare	Shri Ramswaroop Memorial University, Barabanki, Uttar Pradesh, 225001, India
Prabhakaran S	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India
Pallavi Saxena	ICMR- National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, 110029, India

Pradeep K Chaturvedi	Department of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, 110029, India
P. P. Sethumathi	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, 638052-India
Parim Brahma Naidu	Animal Physiology and Biochemistry Laboratory, ICMR-National Animal Resource Facility for Biomedical Research (ICMR-NARFBR), Hyderabad, 500078-India
R Ravindar Naik	ICMR-National Animal Resource Facility for Biomedical Research, Genome Valley, Shamirpet, Hyderabad, 500101-India
N. Ramesh Kumar	Department of Genetics, Osmania University, Hyderabad, Telangana, India
Reeta Varyani	Department of Cardiology, Sri Sathya Sai Institute of Higher Medical Sciences, EPIP Area, Whitefield, Bangalore, India
Sri Bharathi G.S	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India
Sakthi Sundaram S	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India
Sengottuvelu S	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India
SSYH Qadri	ICMR-National Institute of Nutrition, Jamai-Osmania PO, Hyderabad-500007, India
S. Venkanna	Department of Zoology, Osmania University, Hyderabad, Telangana, India
Savitri Vasudev Baikampady	Department of Cardiology, Sri Sathya Sai Institute of Higher Medical Sciences, EPIP Area, Whitefield, Bangalore, India
Sreedevi Gandham	Department of ECE, Siddhartha Educational Academy Group of Institutions, Tirupati, Andhrapradesh, India
S. Vadivukkarasi	Department of Biochemistry, Centre for Biological Sciences, K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Namakkal District, Tamilnadu, 637215-India
S. Jaikumar	Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502-India
S. Sengottuvelu	Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India-638052
Taniya Saleem	Department of Veterinary Parasitology, SKUAST-Jammu, India
Umesh Kumar	School of Biosciences, IMS Ghaziabad, University Courses Campus, Ghaziabad, Delhi NCR, 201015, India
Vinod Kumar	Department of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, 110029, India
V. V. Sathibabu Uddandrao	Department of Biochemistry, Tiruchengode, Namakkal District, Centre for Biological Sciences, K.S. Rangasamy College of Arts and Science (Autonomous), Tamilnadu, 637215, India
Venketesh	Department of Cardiology, Sri Sathya Sai Institute of Higher Medical Sciences, EPIP Area, Whitefield, Bangalore, India

V. V. Sathibabu
Uddandrao

Department of Biochemistry, Centre for Biological Sciences, K.S.
Rangasamy College of Arts and Science (Autonomous), Tiruchengode,
Namakkal District, Tamilnadu, 637215-India

CHAPTER 1

Cardiovascular Diseases and Nutraceuticals: Underlying Mechanism and Therapeutic Biomarkers

Pallavi Saxena¹, Vinod Kumar², Noopur Khare³, Neeraj Pal⁴, Dibyabhava Pradhan⁵, Pradeep K Chaturvedi², Arun Kumar Jain¹, Manoj Kumar⁶, V. V. Sathibabu Uddand Rao⁷ and Umesh Kumar^{8,*}

¹ ICMR- National Institute of Pathology, Safdarjung Hospital Campus, New Delhi, 110029, India

² Department of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, 110029, India

³ Shri Ramswaroop Memorial University, Barabanki, Uttar Pradesh, 225001, India

⁴ GB Pant University of Agriculture and Technology, Pantnagar, Uttarakhand- 263145, India

⁵ ICMR AIIMS Computational Genomics Centre, New Delhi, 110029, India

⁶ Biochemistry Department, Narinder Mohan Hospital and Heart Center, Ghaziabad, Uttar Pradesh, 201007, India

⁷ Centre for Biological Sciences, Department of Biochemistry, K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Namakkal District, Tamilnadu, 637215, India

⁸ School of Biosciences, IMS Ghaziabad, University Courses Campus, Ghaziabad, Delhi NCR, 201015, India

Abstract: Food and nutrients are essential for the body's regular functioning. They aid in the preservation of an individual's health and the reduction of the danger of certain diseases. As a result of the widespread recognition of this fact, a link was established between “nutrition and health,” and the term “nutraceuticals” was coined. Nutraceuticals are therapeutic foods that aid in maintaining well-being, enhancing health, regulating immunity, and preventing as well as curing certain diseases. Nutraceuticals might thus be thought of as one of the missing pieces in a person's overall health. More than any other illness, cardiovascular disease has numerous risk variables that are susceptible to nutraceutical treatment. It is critical to see nutraceuticals' ability to improve cardiovascular risk factors as a huge opportunity in the treatment of a disease that affects so many people. Nutraceuticals show promise in clinical treatment since they have the potential to minimize the risk of chemotherapy-related side effects while also lowering the overall cost of health care. In this study, an attempt was made to summarize some of the most recent research findings on garlic, omega-3 fatty acids, soy products, dietary fibers, vitamins, antioxidants, plant sterols,

* **Corresponding author Umesh Kumar:** School of Biosciences, IMS Ghaziabad, University Courses Campus, Ghaziabad, Delhi NCR, 201015, India; E-mail: umeshkumar82@gmail.com

Dr. V. V. Sathibabu Uddand Rao & Dr. Parim Brahma Naidu (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

flavonoids, prebiotics, and probiotics that have beneficial effects on the heart, as well as to provide insight into a bioinformatics approach to identify novel therapeutic biomarkers in order to keep practitioners up to date.

Keywords: CVD, Diet, Heart disease, Metabolic syndrome, Nutraceuticals, Nutrition.

1. INTRODUCTION

1.1. Cardiovascular Disorders

The term “cardiovascular disorders” (CVD) or “heart disease” refers to a variety of illnesses that affect the heart and blood arteries [1]. Coronary artery disease, cerebrovascular disease, angina, heart attack, heart failure, dilated and hypertrophic cardiomyopathy, peripheral arterial disease, rheumatic heart disease, heart rhythm problems (arrhythmias), congenital heart defects, deep vein thrombosis, and pulmonary embolism are all diseases that fall under the heart disease umbrella. Electrocardiogram (ECG), Holter monitoring, Echocardiogram, Stress test, cardiac catheterization, cardiac computed tomography (CT) scan, and cardiac magnetic resonance imaging are commonly used to diagnose it (MRI) [2]. CVD has surpassed cancer as the top cause of mortality worldwide, and it is a major public health issue. Obesity, metabolic syndrome, atherosclerosis, hyperlipidemia, type 2 diabetes, hypertension, and lifestyle risk factors such as smoking, physical inactivity, and dietary factors are all common and growing in popularity across the world [3]. Reducing risk variables in the population, particularly blood pressure control and cholesterol reduction can have an influence on CVD mortality [4]. Hypertension is to blame for 45% of heart attacks and 51% of strokes, as well as 9.4 million CVD-related deaths throughout the world [5]. Despite significant advancements in medical care, the prognosis for CVD remains dismal, and identifying causes and new therapeutic methods remains a high priority [6].

1.2. Cardiovascular Diseases Burden: Global and National

Cardiovascular diseases (CVDs) are the leading cause of death worldwide and a significant contributor to poor quality of life [7]. CVD claimed the lives of 17.8 million people globally in 2017, resulting in 330 million years of life lost and another 35.6 million years of disability [8]. Heart attacks and strokes account for four out of every five CVD fatalities, with one-third of these deaths occurring before the age of 70 [9]. Furthermore, case fatality due to CVD appears to be

significantly greater in low-income nations than in middle- and high-income countries [10].

The burden of cardiovascular disease (CVD) in India is one of the highest in the world. Noncommunicable diseases (NCDs), including cardiovascular disease (CVD), are projected to account for 60% of all adult fatalities in India, with CVD accounting for approximately 26% of these deaths [11]. The yearly number of CVD fatalities in India is expected to increase from 2.26 million in 1990 to 4.77 million in 2050 (2020). The age-standardized CVD mortality rate in India is 272 per 100,000, which is higher than the global average of 235 per 100,000 [8]. Over the last 25 years, the incidence of CVD risk factors has been significantly increasing in India, particularly in metropolitan areas [12].

Coronary heart disease prevalence rates in India have varied from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations during the last several decades [13]. Ischemic heart disease (IHD) and stroke account for the bulk of CVD mortality in India (83%) [14]. The ratio of IHD to stroke mortality in India is significantly greater than the worldwide norm and equivalent to that in Western developed nations [15]. IHD and stroke account for more than a twentieth (21.1%) of all deaths and one-tenth of all years of life lost in India [16]. The Macroeconomic Commission for Health predicted that the number of IHD patients in India would increase from 36 million in 2005 to 62 million in 2015 (70% increase). In general, India's stroke incidence and stroke-related case fatality rates are greater than those of Western industrialised nations, but the rates among women are especially high. Haemorrhagic strokes are more prevalent in India than in the Western population, according to current neuroimaging research [17].

Hypertensive heart disease, among other cardiovascular diseases, is a serious problem in India, with 1.47 million fatalities in 2019, up 138% from 1990 [18]. Rheumatic heart disease (RHD) is a concern in many regions of India, with an estimated 88,674 fatalities (7 per 100,000 population) in 2010. Though, from 2000 to 2010, the Indian Council of Medical Research (ICMR) began community management and prevention of RHD using hospital-based passive monitoring and secondary prophylaxis as part of the Jai Vigyan Mission Mode Project [19]. At the national level, there is no systematic program for the prevention and control of RHD. However, following adopting an economic liberalization and globalization strategy in 2000, India's socioeconomic situation, improved living circumstances, and increased connectivity and access to health-care institutions are predicted to have resulted in a decrease in the burden of RHD [20]. According to estimates from the Global Burden of Disease research, atrial fibrillation and flutter contribute very little to the total CVD burden in India. Furthermore, other types of

CHAPTER 2**Congestive Heart Failure: Insight on Pharmacotherapy****Sri Bharathi G.S^{1,*}, Sakthi Sundaram S¹, Prabhakaran S¹, Lalitha V¹, Haja Sherief S¹, Duraisami R² and Sengottuvelu S¹**¹ Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India² Department of Pharmacognosy, Nandha College of Pharmacy, Erode Tamilnadu, India

Abstract: Congestive Heart Failure (CHF) is the inability of the heart to supply blood to other organs and tissues to meet its need for metabolism. Over 64.3 million people around the world live with heart failure. Some of the common causes of CHF include myocardial infarction, increase in blood pressure, atrial fibrillation and cardiomyopathy. The complete etiology of CHF is complex. Patients with HF often experience fatigue, dyspnea, and pain, lack of energy, cognitive impairment and depression. Left ventricular ejection fraction (LVEF) is a measure of the amount of blood pumped from the heart's left ventricle during each contraction. It is used as a phenotypic marker in the indication of the pathophysiological mechanism and sensitivity to therapy. The pathogenesis of HF with low ejection fraction is that of a progressive state. The various classes of drugs used clinically for the treatment of congestive heart failure are diuretics, beta blockers, ACE inhibitors and vasopressin receptor antagonists. The management of Heart failure includes acute decompensation, chronic management and palliative care. Cardiac glycosides are a varied group of naturally obtained compounds used in the treatment of CHF. They exhibit their action by binding to and inhibiting Na⁺/K⁺-ATPase. Then, they consequently increase the force of myocardial contraction. The primary structure of these drugs is a steroidal framework, which is the pharmacophoric component that is responsible for their activity. The most familiar cardiac glycosides are digitoxin, digoxin, oleandrin, bufalin, ouabain, marinobufagenin, telocinobufagin and aerobufagenin. Among other cardiac glycosides, digoxin has been proven to improve symptom alleviation, functional capacity, quality of life and exercise tolerance in patients with mild to moderate HF in clinical trials. Early detection and prevention interventions, as well as lifestyle changes, are essential.

Keywords: Cardiac glycosides, Causes, Congestive heart failure, Digoxin, LVEF, Pathogenesis, Treatment.

* Corresponding author Sri Bharathi G.S: Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, 638052-India; E-mail: gsbharathisri98@gmail.com

Dr. V. V. Sathibabu Uddand Rao & Dr. Parim Brahma Naidu (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

1. INTRODUCTION

Heart failure (HF) or Congestive heart failure (CHF) or cardiac failure is classically defined as “Clinical syndrome caused by the inability of the heart to supply blood to the tissues according to the metabolic needs of the tissues”. Heart Failure results from ventricular dysfunction with volume or pressure overload, either separately or together. It also involves circulatory, neurohormonal, and molecular abnormalities [1]. Diastolic dysfunction is defined as a raised end-diastolic pressure in a normal-sized chamber, whereas systolic dysfunction is described as a lower ejection fraction and refers to the inability to fill and relax the left ventricle. Ischemic (Coronary artery disease [CAD]) and non-ischemic (hypertension, thyroid illness, valvular disease, myocarditis, adult congenital heart disease) diseases are the cause of HF [2]. Coronary artery disease or coronary heart disease, including a previous myocardial infarction (heart attack), high blood pressure, valvular heart disease, atrial fibrillation, excessive alcohol consumption, infection, and cardiomyopathy of unclear cause, are all common causes of HF [3]. Coronary artery disease is considered to be the cause of congestive heart failure (CHF) in nearly 65% of patients [4].

Heart failure patients often experience symptoms of fatigue and lack of energy, depression, pain, dyspnea and cognitive impairment. The etiology of heart failure symptoms is complex and is not completely understood. Although most patients suffer worsened dyspnea with episodes of volume overload, HF-related dyspnea and exertional fatigue are not directly related to pulmonary capillary wedge pressure or cardiac output, rather to broader, systemic effects of HF, including generalized myopathy. Some of the symptoms may also overlap with comorbid problems, which are particularly common in older individuals with heart failure. Symptoms reported by HF patients are significantly impacted by depression and by the patient’s perceived control over their condition [5]. LVEF (left ventricular ejection fraction) is a clinically valuable phenotypic trait that indicates underlying pathophysiological processes and therapeutic sensitivity. Heart failure patients are currently classified as having heart failure with reduced (HFrEF; LVEF 40%–49%), mid-range (HFmrEF; LVEF 40–49%), or preserved ejection fraction (HFpEF; LVEF 50%) ejection fraction. Cut-off values are arbitrary and vary from one guideline to the next. The classification of LVEF has been challenged for oversimplifying a complex condition [2].

Congestive Heart Failure (CHF) with left ventricular systolic dysfunction has been the focus of research (LVSD). Heart failure with normal ejection fraction (HFpEF, also known as “preserved systolic function” and “diastolic dysfunction”) has similar pathologic abnormalities in inflammatory and neuroendocrine function [4]. The severity of heart failure can be explained symptomatically. The commo-

nly used system is the New York Heart Association (NYHA) functional classification [6].

CLASS	SYMPTOMS
I	Cardiac disease, but no symptoms and no limitation in ordinary physical activity
II	Mild symptoms and slight limitation during ordinary activity
III	Significant limitation in activity due to symptoms. Comfortable only at rest
IV	Severe limitations. Symptoms even while at rest

1.1. Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM) is a condition marked by left ventricular (LV) or septal hypertrophy in the presence of normal to hyperdynamic systolic function, no ventricular chamber dilation, and no other cardiac or systemic disease that would explain the hypertrophy.

1.2. Left Ventricular Noncompaction (LVNC)

LVNC (left ventricular noncompaction) is a cardiomyopathy marked by LV hypertrabeculation. Normal LV size and systolic and diastolic function can be related to left ventricular noncompaction. In other situations, however, underlying arrhythmias are present.

1.3. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an uncommon cardiomyopathy with an incidence of 1 in 1000 to 1 in 5000 in the general population. ARVC is hypothesised to be caused by mutations in desmosomal genes such as desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), desmocollin-2 (DSC2), and plakoglobin(JUP), which cause problems in cellular adhesion.

1.4. Restrictive Cardiomyopathy (RCM)

According to data from the PCMR, restrictive cardiomyopathy (RCM) is extremely rare in children, affecting only about 5% of paediatric cardiomyopathy patients. The prognosis for these children is frequently poor, and heart transplantation is frequently required [1].

Diet, Inflammation and Cardiovascular Disorders

M Kesavan^{1,*} and HV Manjunathachar^{2,*}

¹ Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh-243 122, India

² ICMR- National Animal Resource Facility for Biomedical Research, Genome Valley, Hyderabad, Telangana-500101, India

Abstract: Diet has been implicated in cardiovascular inflammation and the development of cardiovascular disorders. Several studies have correlated the dietary pattern with cardiovascular disease incidences. Especially high carbohydrate diet consists of refined starches, sugar, and saturated and trans-fatty acids shown to cause vascular inflammation and its related CVDs. To modify or prevent CVD complications, studies have highlighted and recommended a dietary pattern rich in protein and fibers with low carbohydrates. However, the long term effects of these low carbohydrate diets have not been analysed. Further, the diet consumed in Asian countries is rich in spices and they are loaded with antioxidants. Hence, this has to be reviewed thoroughly to conclude on the role of antioxidants in preventing CVDs. Therefore, in this chapter diet-induced inflammation, the role of low carbohydrate and high fat/protein diets in preventing vascular inflammation and their long term effects on health and the usefulness of antioxidants in preventing cardiovascular diseases will be reviewed elaborately.

Keywords: Antioxidants, Atherosclerosis, Dietary interventions, High Carbohydrate diet, Metabolic syndrome, Vascular inflammation.

1. INTRODUCTION

1.1. Diet Induced Inflammation

The Sedentary lifestyle and unhealthy diets of modern society lead to the increased incidence of cardiovascular diseases. Obesity, metabolic syndrome and type-2 diabetes mellitus is on the rise and predisposing for cardiovascular diseases predisposing factors for cardiovascular diseases [1]. Meal ingestion itself causes mild oxidative stress, which leads to the raise in the levels of circulatory

* Corresponding authors Kesavan M & Manjunathachar HV: Division of Pharmacology and Toxicology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh-243 122, India; & ICMR- National Animal Resource Facility for Biomedical Research, Genome Valley, Hyderabad, Telangana-500101, India; E-mails: kesu.kesavan@gmail.com & drmanju.icmr@hotmail.com

inflammatory mediators [2]. It is demonstrated that glucose intake promotes reactive oxygen species generation [3] and full fat meal with saturated fats activates endothelium. It is evident that post-prandial state abnormalities are the major contributing factors for cardiovascular diseases [1]. Although several studies have examined the pro-inflammatory effects of individual macronutrients, it is pertinent to note that all the ingredients of a diet should be considered to get an insight to the overall diet related inflammation. A study by O'Neil *et al.* [4] showed the positive correlation between pro-inflammatory diet and CVDs development in Australian men. Further, saturated fatty acid intake alone did not predict the CVD events. Therefore, dietary inflammatory index scores can be useful for recommending the best-suited diet for CVD predisposed population.

1.2. Dietary Inflammatory Index (DII)

It is a quantitative measurement for assessing diet-associated inflammation, which was first introduced in 2009 and subsequently, several modifications and additions were made. Basically, it scores the inflammatory values of dietary ingredients and classifies them as pro-inflammatory or anti-inflammatory. DII scores are comparable with the Alternative Healthy Eating Index or Mediterranean Diet (MED) score and moderately correlated with the glycemic index score. However, a moderate negative correlation was observed between DII scores and Healthy Eating Index and Mediterranean Dietary Index. Albeit, updated DII is said to be superior to the other indices as it has considered different population and their diets and the experimental evidence [5]. Including a large population and their dietary patterns and experimental evidence of individual macro/micro nutrients showing pro/ anti-inflammatory effects will provide a robust DII.

Diets consisting of a high amount of saturated and trans unsaturated fatty acids like red meats, hydrogenated fats, refined oils and high glycemic index carbohydrates, has been positively associated with dietary inflammation, while diets based on fruits, vegetables, unsaturated fatty acids, fish, yoghurt, whole grains and wine tend to reduce cardiovascular inflammation. Micronutrients such as omega-3 fatty acids, vitamins B1 (thiamine), B2 (riboflavin), B3 (niacin), folic acid, vitamin A, vitamin C, vitamin E, beta-carotene, magnesium, and zinc are proven to be anti-inflammatory [6 - 8].

2. DIFFERENT PATTERNS OF DIET AND THEIR CHARACTERISTICS

Globally several diet patterns are being practiced. Among them, a few diet patterns are practiced especially for weight reduction, weight gain and prevention

of lifestyle diseases. In Ayurveda, dietary plan is one of the principles being followed for treating diseases.

2.1. The Zone Diet

This diet consists of low carbohydrates with protein and fats. This has a fixed percentage of carbohydrates (40%), protein (30%) and fat (30%) in everyday meal. This diet plan is similar to our ancestor's diet where, meat, vegetables and fruits were their dietary sources [9]. The zone diet consists of carbohydrates from unrefined cereals and fats. As the major energy source in this diet is shifted from carbohydrates to fats, a better control of blood sugar and weight loss can be achieved. The zone diet also said to be anti-inflammatory and healthy insulin to glucagon ratio can be maintained. This eventually leads to a decline in chronic disease risk, immuno-competency, better physical and mental health, longevity and lifelong weight control [10].

2.2. Ketogenic Diet

The ketogenic diet is said to cure some medical conditions like Alzheimer's disease, cancer, polycystic ovary syndrome, epilepsy, *etc.*, However, it was initially prescribed for controlling diabetes. The ketogenic diet is distinct from the zone diet with its exceptionally high-fat content (70% to 80%), Generally, ketogenic diets consist of 70-80% fat, 5-10% carbohydrate and 10-20% protein [11]. Unsaturated fatty acids or healthy fats-rich foods like avocados, coconuts, brazil nuts, oil seeds, fish and olive oil are added as a part of the diet plan. This diet artificially creates a condition called ketosis. Wherein the absence of glucose for generating energy leads to the breakdown of fats and the formation of ketone bodies [12]. This diet plan can be used for reversing metabolic syndrome such as insulin resistance, high blood pressure, dyslipidemia. Along with this, weight loss can be achieved in a very short period time. Ketogenic diet and other low carbohydrate diets are being focused on controlling type 2 diabetes [13, 14].

2.3. Mediterranean Diet

The Mediterranean diet is being followed among the people of Crete, Greece, and southern Italy, which are the populations bordering the Mediterranean Sea. Further, this pattern of diet is also consumed in Spain, southern France, and Portugal. It is primarily plant-based diet that includes whole grains, olive oil, fruits, vegetables, beans, legumes, nuts, herbs, and spices in their regular meal. In 1993, the Harvard School of Public Health, Old ways Preservation and Exchange

Rodent and Non-Rodent Animal Models for CardioVascular Diseases

Irfan Ahmad Mir^{1,*}, HV Manjunathachar^{1,*}, R Ravindar Naik¹, SSYH Qadri² and Taniya Saleem³

¹ ICMR-National Animal Resource Facility for Biomedical Research, Genome Valley, Shamirpet, Hyderabad, 500101, India

² ICMR-National Institute of Nutrition, Jamai-Osmania PO, Hyderabad-500007, India

³ Department of Veterinary Parasitology, SKUAST-Jammu, India

Abstract: Cardiovascular diseases (CVD) come under non-communicable disease (NCD) that are responsible for the leading cause of death, globally. They involve a range of pathologies viz. coronary artery disease, cerebro-vascular disease, venous thrombo-embolism, peripheral vascular disease, myocardial infarction, cardiac arrhythmias and stroke. Each pathology is the result of the complex interplay of many factors which determine the prognosis of the condition. Animal experimentation has played an important role in the fundamental understanding of pathologies of cardiac diseases and discovered improved methods of diagnosis and treatment. Researchers have used a number of lab animals that involve rodents (mice, rats, hamsters, and rabbits) and non-rodent animal models (dogs, pigs, sheep, primates) as a biological system to mimic cardiovascular diseases for translational research. An ideal animal-model system should be cheap, readily manipulable, reproducible, ethically sound and reflect the complexity of cardiovascular diseases. Rodent animal models are considered the prime model for human research. Common rodent models include mice, rats and hamsters; rabbits are used for studies on cardiac hypertrophy, heart failure, aortic constriction, pulmonary vein constriction, atherosclerosis and cholesterol regulation studies. With the advancement in genetic engineering, several transgenic/humanized rodent models are available which can mimic better human systems for translational application. Among non-rodent animal models, pigs, dogs, sheep, and non-human primates serve as an excellent model in cardiovascular research; owing to the similarity in heart structure, atrio-ventricular valves, lipid metabolism and vasculature with humans. In the current chapter, we will deal with the importance of the models and their characteristic features, advantages and limitations.

Keywords: Animal Models, Cardio-vascular Diseases, Non-Rodents, Rodents.

* Corresponding authors Irfan Ahmad Mir & HV Manjunathachar: ICMR-National Animal Resource Facility for Biomedical Research, Genome Valley, Shamirpet, Hyderabad, 500101, India; E-mails: mirirfan441@gmail.com & drmanju.icmr@hotmail.com

These authors have equal contribution.

Dr. V. V. Sathibabu Uddandrao & Dr. Parim Brahma Naidu (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

1. RODENT MODELS FOR CVD

Cardiovascular diseases (CVDs) are the leading principal cause of death and morbidity, globally. CVDs are a group of disorders of the heart and blood vessels that include coronary heart disease, cerebro-vascular disease, rheumatic heart disease, and other conditions. About 17.9 million people die annually (approximately 31%) due to CVDs. More than three-quarters of deaths occurring in low- and middle-income countries are due to cardiovascular diseases, depicting a serious burden on the medical field. The etiologies for cardiac and vascular complications are very complex, in which both genetic and environmental factors are implicated along with lifestyle changes [1]. Generally overweight, increased blood pressure and blood sugar level may cause cardiovascular diseases and they are categorized under two major disorders belonging to lipid metabolism and metabolic syndromes [2].

The use of animal models has contributed immensely to increasing the knowledge about pathophysiology and focused approaches to improve the diagnostic and the early treatment of diseases [3]. The CVDs' preventative and ameliorative treatments depend on animal models that mimic human disease processes. Generally, rodents are widely accepted as the model organism for studying the diseases of humans, especially for mice, with whom they share 99% of their genes. Rodents have been regarded as a reliable research species mainly due to their small size, abbreviated (short) lifespan, reproductive affluence, known genetic background, as well as ease in handling and housing practices. With the development of biotechnologies and medico-veterinary field, various manipulations allow the establishment of rodent models which accurately mimic the human disease model of interests and accurately reflect the morphological and biochemical aspects of disease pathogenesis [4 - 6]. Experimental rodent models are widely used for cardiovascular diseases research due to the effective simulation of human cardiovascular diseases, stronger reproductive ability, and detection of physiological indicators in contrast to large animal models [7]. Henceforth, in this article, we will summarize the most common models of cardiovascular diseases, and modeling methods to provide a reference for research on cardiovascular diseases. In particular, we will briefly describe atherosclerosis and diabetic models, with models of heart failure.

2. ATHEROSCLEROSIS AND DIABETIC MODELS

Atherosclerosis is a chronic inflammatory condition and one of the underlying factors of cardiovascular diseases. Atherosclerosis is a disease in which plaque builds up inside human arteries. Both the blood vessel walls and the immune

system are implicated in atherogenesis. Plasma lipoproteins, genetics and the hemodynamics of the blood flow in the artery all play important roles in the development of atherosclerosis. Animal models are valuable tools for providing insights into the etiology and pathophysiology of this disease. They can be used for testing the efficacy and safety of different pharmacological therapies. As per the extensive literature survey, mouse models particularly knockout and transgenic mouse models for atherosclerosis have proved to be useful to study the development and progression of the atherosclerotic lesion, understand the molecular and cellular mechanisms involved in atherogenesis, and evaluate the effectiveness of new and existing atherosclerotic drugs [8].

Generally, wild-type mice are resistant to atherosclerotic lesion development. The current mouse models used for atherosclerosis are based on genetic modifications of lipoprotein metabolism with additional dietary changes. Among them, low-density lipoprotein receptor-deficient mice (LDLR^{-/-} mice) and apolipoprotein E-deficient mice (apoE^{-/-} mice) are the most widely used mouse models for atherosclerosis research. Both LDLR and APOE are important for the removal of cholesterol and triglyceride-rich lipoprotein particles from the blood. APOE is a plasma glycoprotein constituent on the surface of most lipoproteins including very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and chylomicron lipoprotein particles. LDLR is a cell-surface receptor that recognizes the ApoE, apoprotein B 100, and apolipoprotein B (APOB) to clear the lipoprotein particles from the blood. Human mutations in LDLR and APOE are associated with several hereditary dyslipidemic disorders and increase the susceptibility to atherosclerosis for the mutation carrier.

2.1. LDLR^{-/-} Mice

The LDLR^{-/-} mice (low-density lipoprotein, LDL, receptor) are the models for studying familial hypocholesterolemia [3]. These models have a mutation that affects the LDLR level and resembles humans' plasma lipoprotein profile. The genetic modification in the model leads to delayed clearance of very-low-density lipoprotein (VLDL) and LDL from the plasma and therefore results in an increased plasma level of cholesterol on the normal chow diet [9]. Besides, the inclusion of high-fat and high-cholesterol content in the diet increases the severity of atherosclerotic lesions and hypercholesterolemia in LDLR^{-/-} mice [10]. The plasma levels of LDLR^{-/-} mice fed on a high-fat western diet were 10 times higher than those of wild type, and plaques formed on the aortic roots, showing symptoms of atherosclerosis. Pan *et al.* fed 7-week-old male LDLR^{-/-} mice (C57BL6/J background) with a western diet containing 20% fat, 20% sugar, and 1.25% cholesterol till 16 weeks of age. The evaluation of aortic atherosclerotic

CHAPTER 5

Application of 21st Century Genetic Engineering Tools and CRISPR-Cas9 Technologies to Treat Most Advanced Cardiovascular Diseases of Humans**J. Venkateshwara Rao^{1,*}, R. Ravindar Naik², S. Venkanna¹ and N. Ramesh Kumar³**¹ Department of Zoology, Osmania University, Hyderabad, Telangana, India² ICMR-National Animal Resource Facility for Biomedical Research, Genome Valley, Shamir pet, Hyderabad, 500101, India³ Department of Genetics, Osmania University, Hyderabad, Telangana, India

Abstract: 21st Century Genome-editing technologies have been rapidly emerging as the most powerful tool capable of creating genetically altered cells or organisms for explicit gene functions and mechanisms for causing several human ailments. While clinical gene therapy celebrates its first taste of success, with several products approved for clinical usage and several thousands of them awaiting stages in pipelines, unfortunately, there are no gene therapy treatment methods available for many cardiovascular diseases (CVD). Despite sustained medical advances over the last 50 years in CVD, the main cause of death is still uncertain in the developed world. The management of genetic expression by using small molecule RNA therapeutics and the development of accurate gene corrections may lead to several applications, such as cardiac revitalization after myocardial infarctions and gene corrections for the inherited cardiomyopathies but certainly with some limitations. CRISPR/Cas9 technology can be utilized to realign DNA modifications ranging from a single base pair to multiple pairs of mutations in both *in vitro* and *in vivo* models. This book chapter emphasizes various types of applications by CRISPR technologies in cardio-vascular research, and genome-editing novel therapies for future medicines.

Keywords: CRISPR/Cas9, Myocardial infarction, Gene Therapy, Myocardial infarction, Induced pluripotent stem cells (iPSCs).

* Corresponding author J. Venkateshwara Rao: Department of Zoology, Osmania University, Hyderabad, Telangana, India; E-mail: venbio@gmail.com

Dr. V. V. Sathibabu Uddand Rao & Dr. Parim Brahma Naidu (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

1. INTRODUCTION

Gene editing technologies are promising methods to investigate disease mechanisms at the gene level. By employing these technologies, scientists could introduce, modify or remove mutations at specific locations or points of the target gene and can make a successful model disease organism to prevent the incidence of many diseases. In 1996, the First and Second generations of Gene Technologies *i.e.*, transcription activator-like effector nucleases (TALEN's) and zinc-finger nucleases (ZFN's) evolved independently. However, the high costs and also low efficiencies involved in their procedure have restricted their accessibility and usage in various applications [1]. In 2013, CRISPR technology emerged as the 3rd generation of gene-correcting methods and has been quickly put to use by various scientists for its merits of high efficacy, speed, and cost reduction [2]. In recent times, this modern CRISPR technology has been applied to many fields such as agriculture, drug design, and discovery and medical research [3].

Exploring the genetic basis of several diseases will enable significant inputs into medical research. The successful finishing of the Human Genome Project (HGP) and the DNA sequencing knowledge extracted from several patients have allowed us to understand the relationships between genetic components and human diseases [4]. Alternations and genetic mutations in over 3000 genes that are linked to many diseases and disorders in humans have already been studied [5].

In contrast to cancer and diabetes, which are multifactorial illnesses brought on by a variety of genetic alterations and environmental factors, Huntington's disease, Thalassemia, Sickle Cell Anemia, and Cystic Fibrosis are monogenetic genetic disorders caused by the mutation of a single gene [6]. Unfortunately, there are many disorders without appropriate treatments. However, Genomic therapies can offer potential and effective therapeutic tools to fight many genetic diseases [4] and it is now the first and foremost choice of many medical practitioners and incorporates refinement of target genetic corrections by using precise gene editors. Genetic therapies sketchily include the deletion of a faulty gene or group of genetic alterations by incorporation of external DNA and correcting the changed gene at the inherent site [7]. Despite the benefits of this technology, there are several flaws and challenges associated with the applications that make the insertion of exogenous DNA risky. Some of the negative outcomes with unwanted implications include the insertion and activation of off-target gene modifications and erroneous findings generated by the induced genes. Additionally, only a few hereditary diseases are still the exclusive beneficiaries of direct applications nowadays [7].

However, gene correction creates a completely new field for modifying human genetics and gene therapy. It is a novel approach that modifies certain target sequences with alterations that are target-oriented and exact. Future research on genetically based medications may provide new therapeutic approaches for treating a variety of human ailments [7]. The primary method of gene correction involves DNA double-strand breaks (DSB) induction and endogenous cellular repair processes [8]. These cut breaks are classically repaired by either of two major pathways: Non-Homologous End Joining (NHEJ) or Homology-based repair (HDR). To target gene-editing technologies, the most critical component is the identification of precise DSB. Currently, four major methods are employed to initiate target-specific DSB's which include Zinc finger nucleases (ZFNs), engineered mega nucleases, Transcription Activator-Like Effector Nuclease (TALENs), and most recently CRISPR/Cas9 systems [7, 8]. The precise targeting of genetic changes in cultured cells, plants, and animals has been made possible by these new methods. CRISPR technologies are superior to other genome-editing techniques because they are less complicated and do not require expensive designed enzymes for each each DNA target locus [8]. In CRISPR technology, the exact results could be achieved by target-oriented RNA and a restriction enzyme mixture represented briefly as Cas9, which is one of the best and most remarkable gene-editing platforms [1]. For the past few decades, the CRISPR system is being applied to many biomedical problems, aimed at developing new curing technologies for monogenic and as well as for multi-factorial diseases [7].

Thus, CRISPR/Cas9 technology can be used in the development of various animal disease models for research purposes to represent diseases or to understand disease progress pathways, by mutating or silencing the relevant genes [2]. However, recently, the horizons of the CRISPR tool were expanded for correcting genes of human embryos as well. The path-breaking discovery of the ability to repair a mutation in the (OCT4 gene)4 octamer-binding transcription factors, a gene involved in the development of the human placenta in a human embryo using CRISPR/Cas9 technology, implies immense clinical potential in the future for treating human genetic diseases [3].

Although CRISPR technologies have been identified as the most successful gene therapy tools currently, some problems have surfaced like its reproducible capabilities and human ethical issues, chiefly concerning editing human germ lines [3]. Several impacts of off-side target cleavages are the primary setbacks of the target system and may restrict its usage for some of the therapeutic applications. In light of this, this review emphasizes the current state and future prospects of CRISPR uses in individualized medicine. The review also focuses on the use of CRISPR technologies as the primary therapeutic tool for a number of human diseases and disorders and summarizes its applications in gene therapies,

Role of Vyana Vayu in CardioVascular System, Etiopathogenesis and Therapeutic Strategies: An Ayurveda Perspective

Savitri Vasudev Baikampady^{1,*}, C. S. Hiremath¹, Reeta Varyani¹ and Venketesh²

¹ Department of Cardiology, Sri Sathya Sai Institute of Higher Medical Sciences, EPIP Area, Whitefield, Bangalore, India

² Department of Biosciences, Sri Sathya Sai Institute of Higher Learning, Prashanthi Nilayam, Puttaparthi, Andhra Pradesh, India

Abstract: A systems approach to health is the hallmark of Ayurveda. It believes in preventing disease and maintaining and restoring health. The entire concept stands on three fundamental functional units-*Vata*, *Pitta* and *Kapha*, where *Vata*, mobilizes the other two units. Depending on their locations, *Vata (Vayu)* is classified into five subtypes, where each has its distinct role to perform. *Vyana Vayu (VV)*, an important subtype of *Vata*, is synthesized in myocytes and responsible for the genesis of the action potential. A key regulator in contractile functions, VV propels out nutrients from the heart. It not only mediates intracrine and paracrine activities but modulates the vascular tone too. Wherever there is scope to flow, VV has its unique role to contribute. Ancient scholars of *Ayurveda* have identified its ubiquitous role in the endogenous system, where all the activities depend on VV. Hence, preventing VV from any stimulus is of paramount importance since they consequently lead to various cardio vascular diseases (CVD). Classical texts have addressed the prognosis in six discrete phases where each phase can be avoided strategically. Highlighting the precipitants that attenuate VV, we focus on addressing those phases along with curative measures so that the functions of *Vyana Vayu* can be restored.

Keywords: Contractile functions, Phases of prognosis, Preventive cardiology, Vascular tone, *Vyana Vayu*.

1. INTRODUCTION

A systems approach to health is the hallmark of *Ayurveda*. It carries the rich tradition of knowledge with epistemological values based on life principles more

* Corresponding author Savitri Vasudev Baikampady: Department of Cardiology, Sri Sathya Sai Institute of Higher Medical Sciences, EPIP Area, Whitefield, Bangalore, India; E-mail: ayurvedsavitur@yahoo.co.in

than 3500 years from date [1]. Theories and concepts postulated by *Ayurveda* scholars are valid even today despite the absence of diagnostic tools and gadgets during their times. It has a comprehensive outlook towards every individual that embraces physical, physiological, and spiritual components. Expressed in Sanskrit, there is a need to comprehend the knowledge and translate it scientifically in the present state-of-art as its affluent intellectual property cannot be possessed only by Sanskrit scholars. Its proficiency lies in the appropriate use for mankind.

The entire concept of *Ayurveda* stands on three fundamental pathophysiological units-*Vata*, *Pitta* and *Kapha*, where *Vata*, mobilizes the other two. *Vata* is expounded to hold the living system [2], comprising gaseous components, moving through a specific cavity [3]. The gamut of its action is always associated with locomotion (*Gati*). Based on the extent of operations, *Vata* is classified into five subtypes, where each constitutes an independent system with a distinct role to perform [4]. Even though each subtype is confined to perform in a given territory, the *Vyana Vayu* (VV), a unique subtype of *Vata* has a wider role to perform throughout the body. VV is an indigenous component of the heart (*Hridaya*), responsible for contractile functions. It is due to VV that the heart relentlessly (*Ajasram*) pumps out required nutrients to fulfill the metabolic demands. Diffuse (*Krutsna dehachari*) in nature, VV plays a central role in maintaining homeostasis in the circulatory system (*Rasasamvahana*). It protects the cardiovascular system (CVS) and metabolic system (MS) through anti-inflammatory and anti-oxidant properties [5 - 8]. The slightest imbalance in the bioavailability of VV can give rise to serious pathological conditions. Several intrinsic and extrinsic factors (IEF) can exasperate the balanced state, invoking the pre-determinants of cardiovascular and metabolic disorders (CMD) [9]. Deleterious effects on CMD can be negated if VV's intrinsic properties are preserved. Hence, knowledge of the realm of VV on CVS and MS could provide an alternative approach to detect the prognosis of CMD with complications. Since every cardiac patient has the potential to develop heart failure, there is a need to explore new areas on predisposing factors that leads to CMD prognosis.

If the etiological elements are not curtailed in time, CVD will remain to be the leading cause of death for the next ten years of more than 100 million populations [10, 11]. There is a general agreement that these factors are modifiably associated with environment and lifestyle. WHO has initiated several awareness programs to abridge CVD and its risks, but despite this awareness, there has not been any decline in the number of CVD cases. Technological advancements have considerably improved survival rates from acute cardiovascular events, but surviving inhabitants with compromised functions of the heart have simultaneously increased.

Hence, intending to prevent CMD prognosis and improving the quality of life of survived victims, we explore the knowledge of Ayurveda to extend the horizon of etiology and provide a broader scope for prevention. This can be understood in six discrete phases of pathogenesis where each phase can be strategically avoided. This chapter highlights the analysis of *Vyana Vayu* from physiological and etiopathological aspects, followed by concomitant contemporary concepts and therapeutic strategies.

2. A PREAMBLE TO VATA

The very existence of *Vata* in the endogenous system denotes life. Whether voluntary or involuntary, all actions are governed by *Vata*, right from attending to gross functions such as breathing, swallowing food, belching, sneezing, coughing or excretion of wastes, and many more [12]. It contributes to the manifestation of shape, cell division, cell signaling, and cognition [13]. Processes involving conduction of impulse, metabolite transport, scavenging of free radicals, apoptosis, and necrosis are all governed by it [14]. Due to its gaseous property, it acquires a natural tendency to arid (*Ruksha*). This prevents the cellular components from over-lubrication, at the same time facilitates apoptosis appropriately. Highly unstable (*Chala*), subtle (*Sukhma*), and dynamic nature of *Vata* varies with time and places of action [15, 16]. Even though it maintains the body's thermal equilibrium by cooling (*Sheeta*), it is highly sensitive to extreme temperatures [17]. Its proficiency is best demonstrated with optimum bioavailability (*Sama*) but becomes pathologic and devastating otherwise (*Vruddhi. Kshaya*) [18]. Whether intracellular or extracellular, the quantum of its kinetic nature is demonstrated through diverse actions.

2.1. Vyana Vayu

The human system is uniquely designed, where all actions are performed through well-defined, well-coordinated, intact, and enclosed channels (*Srotas*) [19]. VV is believed to be activated and spread indefinitely across these intact channels, where ever there is scope to flow. VV facilitates cell trafficking, membrane trafficking, and the exchange of blood to and from the heart (*Gamanaagaman kriya*) and establishes communication between the substrate and circulating metabolite. Whether an organ designed for a specific task or a circulating channel carrying metabolites to the target tissue, VV has its extensive role to perform in it. This is possible only if VV is expressed on the surface of any flowing channel. Classical authors have unanimously expounded on the diffuse nature of VV that originates and regulates several functions from the heart (*Hrdaya*). Whether the intracrine or paracrine, *Vata* must be functional in space. Furthermore, whether

CHAPTER 7**Nutraceuticals: The Potential Agents to Rescue Human Race from Cardiovascular Diseases (CVDs)****Sreedevi Gandham¹, Ghali. EN.Hanuma Kumar² and Balaji Meriga^{2,*}**¹ Department of ECE, Siddhartha Educational Academy Group of Institutions, Tirupati, Andhrapradesh, India² Department of Biochemistry, Sri Venkateswara University, Tirupati, Andhrapradesh, India

Abstract: Cardiovascular disease(CVD) is the foremost global health problem that accounts for the highest rate of morbidity, mortality and huge healthcare costs. Food habits and lifestyles predominantly affect the functioning of the cardiovascular system either directly or indirectly through risk factors like hypertension, obesity, dyslipidemia, diabetes, *etc.* Decreased physical activity, increased sedentariness, and growing fast food culture are some of the apparent reasons that make the disease impact more on the younger generation. Several plant species have been reported in ethnomedicine for their therapeutic efficacies against CVDs and other diseases. Even though some preclinical and clinical studies have demonstrated the beneficial effects of dietary plant components in the prevention and treatment of CVDs, they are limited to selected study groups. Therefore, their scope and utility need to be broadened and applied to larger populations to reduce the public health burden of CVDs. Since nutraceutical approach is more preferable than other therapeutic methods, there is a growing interest in functional foods and diet based remedies. In the present chapter, we have presented the current scenario of CVDs, their pathophysiology, the therapeutic drugs available, the role of nutraceuticals in treating CVDs and their mode of action with a special emphasis on commonly used kitchen spices.

Keywords: CVDs, Dyslipidemia, Hypertension, Nutraceuticals, Phytoconstituents, Spices.

1. INTRODUCTION

In recent decades, with advancements in science and technology, human lifestyle has changed dramatically in both developed and developing countries. The consumption of fast foods/energy dense foods, snacking frequency and late night

* Corresponding author **Balaji Meriga:** Department of Biochemistry, Sri Venkateswara University, Tirupati, Andhrapradesh, India; E-mail: balaji.meriga@gmail.com

meals and snacks have increased. Simultaneously, physical exercise has considerably reduced due to increased conveyance facilities, availability of high end machinery, tools and electronic devices used in every sphere of human activity [1]. As a result, the environment sensed by the brain has become arrhythmic. Taken together, the incidence of CVDs and other metabolic syndrome disorders has been alarmingly rising across the globe [2].

Cardiovascular diseases (CVDs) are a cluster of disorders of blood vessels and heart, including peripheral heart disease, coronary heart disease, cerebrovascular disease (stroke), heart failure, heart attack, cardiomyopathies, congenital heart disease and dyslipidemias. CVDs majorly occur due to impairment in blood supply to organs like the heart or/and the brain because of atherosclerosis, thrombosis and high blood pressure. Fig. (1) shows some principle reasons for the occurrence of cardiovascular diseases. As per the WHO report in 2017, CVDs caused 31% annual deaths worldwide. According to the European cardiovascular disease statistics, more than 45% of deaths occur due to CVDs in Europe [3]. In the USA, about 50% of population suffers from one or other form of CVDs as per the American Heart Association report [4]. In India, with more than one billion population and with a high incidence of abdominal obesity, diabetes and hypertension, the CVD morbidity is on the brink of turning into an epidemic [5]. The annual number of deaths from CVDs in India is projected to rise from 2.26 million (1990) to 4.77 million or more by 2020 [4]. Worldwide distribution of various cardiovascular diseases is represented in Fig. (2).




Fig. (1). Principle reasons of CVD.




Fig. (2). Worldwide distribution of various CVD.

The common risk factors for CVDs include physical inactivity, obesity, hypertension, ethnic background, family CVD history, smoking, hyperlipidemia, elevated levels of low-density lipoprotein (LDL) cholesterol, reduced levels of high-density lipoprotein cholesterol (HDL) and diabetes [6]. Recent studies confirmed inflammation as a prominent risk factor which is indicated by high levels of highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) [7]. Basic symptoms include pain or discomfort in the centre of the chest, arms, left shoulder, jaw and elbows, difficulty in breathing, vomiting or feeling sick, faintness, dizziness and unconsciousness.

2. CVDS: PATHOPHYSIOLOGY

The main pathogenic process identified in CVD patients is atherosclerosis caused by the decreased or lessened blood flow in the blood vessels in the aorta and the arteries. Fig. (3) represents the narrowing of arteries due to plaque deposition. Atherosclerosis involves inflammation, endothelial dysfunction, immunologic phenomena and dyslipidemia [8]. A dysfunctional endothelial system causes the deposition of LDL particles and their conversion into oxidized LDL in the intima of blood vessel walls. They trigger the development of fatty plaques due to the accumulation of extracellular matrix and lipid-laden macrophages. It leads to further macrophage recruitment that becomes calcified and transition to

Ameliorative Potential of Biochanin-A against Dexamethasone Induced Hypertension through Modulation of Relative mRNA and Protein Expressions in Experimental Rats

V. V. Sathibabu Uddandrao^{1,*}, P. P. Sethumathi², Parim Brahma Naidu³, S. Vadivukkarasi¹, Mustapha Sabana Begum⁴ and G. Saravanan^{1,*}

¹ Centre for Biological Sciences, Department of Biochemistry, K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Namakkal District, Tamilnadu, 637215, India

² Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamil Nadu, 638052, India

³ Animal Physiology and Biochemistry Laboratory, ICMR-National Animal Resource Facility for Biomedical Research (ICMR-NARFBR), Hyderabad, 500078, India

⁴ Department of Biochemistry, Muthayammal College of Arts and Science, Rasipuram, Namakkal, Tamil Nadu 637408, India

Abstract: In this study, we made an attempt to attenuate the dexamethasone induced hypertension through Biochanin-A (BCA) in experimental rats. Hypertension was induced in male albino Wistar rats by subcutaneous administration of dexamethasone (10µg/kg body weight). The rats were orally treated with BCA (10mg/kg body weight) once daily for 45 days and Nicorandil-treated group (6mg/kg body weight) included for comparison. We evaluated the changes in mean arterial pressure, heart rate, blood pressure, vascular function, oxidative stress markers, and gene expression of histone deacetylases (HDAC)-1, HDAC-2, and HDAC-8. Administration of BCA or Nicorandil showed noteworthy improvement in vascular function in experimental rats. Moreover, aortic eNOS expression was down regulated, and NADPH oxidase subunit p47^{phox} was up regulated in hypertensive rats. The antihypertensive effects of BCA were connected with concomitant downregulation of p47^{phox} expression and upregulation of eNOS expression. Dexamethasone exposure led to increased mRNA expression of HDACs expression in the kidneys and these were restored after BCA administration. In conclusion, our results are, therefore, BCA reduces hypertension in experimental rats and suggests that BCA might be used against the hypertension.

Keywords: Biochanin-A, Hypertension, Natural products, Vascular dysfunction.

* Corresponding authors V. V. Sathibabu Uddandrao & G. Saravanan: Centre for Biological Sciences, Department of Biochemistry, K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Namakkal District, Tamilnadu, 637215-India; E-mails: sarabioc@gmail.com & sathibabu.u@gmail.com

Dr. V. V. Sathibabu Uddandrao & Dr. Parim Brahma Naidu (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

1. INTRODUCTION

Hypertension is a disorder provoked by several factors, which belong to the foremost threat factors dependable for renal dysfunction, cardiovascular and metabolic diseases [1]. There are numerous substantial researches presenting the significance of vascular tone rise through the sympathetic nervous system and the renin angiotensin pathway in vital hypertension. Vascular tone is mostly reliant on the intracellular Ca^{2+} levels in vascular smooth muscle cells, which are synchronized by the endothelium, an essential module of the blood pressure and vascular wall [2]. The endothelium liberates vasodilators, together with prostaglandin I₂, endothelium-derived hyperpolarizing factor, and nitric oxide (NO), as well as vasoconstrictors, such as endothelin, angiotensin-2 and thromboxane-A₂, an extremely strong vasoconstrictor [3]. In normal states, the vascular quality is maintained by constrictor signals and vasodilator [4]. Nevertheless, in disease conditions, an increase in the endothelium-derived and a reduction in the endothelium-attained vasodilators or inflamed tissue-derived vasoconstrictors subsequently raise blood pressure and vascular tone, and leads to hypertension. In fundamental hypertension, systolic and diastolic blood pressures elevation is reassured by the combination therapy of angiotensin converting -adrenergic receptor blockers, diuretics, and β -enzyme inhibitors, angiotensin receptor blockers [5, 6]. On the other hand, the effectiveness of conventional antihypertensive agents cannot be expected in salt sensitive hypertension, reasonable to brutal hypertension, and metabolic disease induced hypertension to go together with endothelial damage [6]. For that reason, novel anti hypertension medications are necessary to combat against relentless and convoluted hypertension.

Biochanin-A (BCA) is a natural compound that is predominantly found in soy, chickpea, peanuts, alfalfa sprouts, and red clover. It is chemically known as Omethylated isoflavonoid and has several benefits against myocardial infarction [7], antiobesity [8] and obesity cardiomyopathy [9]. However, there was no scientific literature available to point out the antihypertensive efficacy of BCA. Hence, the present study is to evaluate the antihypertensive potential of BCA in dexamethasone (DMS)-induced hypertension in experimental rats.

2. MATERIALS AND METHODS

2.1. Chemicals

BCA was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). All the reagents used in the experiments were analytic grade and had the highest purity.

2.2. Animals

Male Wistar rats were obtained from the Department of Biochemistry, Muthyammal College of Arts and Science, Rasipuram, Namakkal District, Tamilnadu, India. Experimental animals were kept under standard laboratory conditions (temperature; $22\pm 2^\circ\text{C}$; moistness; 40-60%), and permitted food and water *ad libitum*. Rats, at first weighing 180-200g, were separated into four groups of six each (n=6). All procedures involving laboratory animals were in accordance with the institutional animal ethical committee of Muthyammal College of Arts and Science (Approval number: IAEC/MCAS/07/2019).

2.3. Induction of Hypertension

In the experimental rats, hypertension was induced by subcutaneous injection of DMS ($10\mu\text{g/kg/d}$) in the evening [10].

2.4. Experimental Design

Group I: Normal control

Group II: Hypertensive control

Group III: Hypertensive + AA (20mg/kg body weight)

Group IV: Hypertensive + Nicorandil (6mg/kg body weight)

2.5. Measurement of Body Weight

The body weight of each rat was measured. At the end of the experiment, blood was collected from overnight fasted animals under inhalation of anaesthesia by retro-orbital puncture method. Blood was collected in anticoagulant coated vials and permitted for 15 minutes at room temperature. Plasma was separated by centrifugation at 2500 rpm for 15 minutes.

2.6. Indirect Measurement of Blood Pressure in Conscious Rats

Systolic blood pressure (SBP) of rats was determined every week end by non-invasive tail-cuff plethysmography (IITC/Life Science Instrument, USA). In short, awakened rats were positioned in a restrainer when quiet just before measurement. The rat tail was positioned within the tail cuff, and the cuff was

CHAPTER 9

Zingiberene, an Active Constituent from *Zingiber officinale* Ameliorated High-Fat Diet-Induced Obesity Cardiomyopathy in Rats

S. Jaikumar¹, G. Somasundaram¹ and S. Sengottuvelu^{2,*}

¹ Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502, India

² Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, India

Abstract: In the current study, we evaluated the effect of Zingiberene (ZB) is, a monocyclic sesquiterpene that is the principal constituent of ginger (*Zingiber officinale*), against high-fat-diet (HFD)-induced obesity cardiomyopathy (OC) in rats. ZB (50mg/kg/BW) was supplemented on obese rats for the period of 45 days and assessed its effect of body weight, anthropometrical and morphological parameters along with hyperglycemic markers. We also evaluated the effect of ZB on cardiac lipotoxicity and oxidative stress in cardiac tissue. The current study demonstrated that HFD supplementation significantly increased body weight, anthropometrical and morphological parameters, together developed hyperglycemia in rats. On the other hand, ZB supplementation in obese rats attenuated these altered parameters and ameliorated cardiac lipotoxicity as well as oxidative stress by decreasing lipid profiles of heart and enhancing the activities of endogenous antioxidant enzymes in the heart. Therefore, this study suggest that ZB might ameliorate the diet induced OC through the restoration of antioxidant system of the heart and attenuation of dyslipidemia in the cardiac.

Keywords: Nutraceuticals, Obesity cardiomyopathy, Oxidative stress, Zingiberene.

1. INTRODUCTION

Obesity cardiomyopathy (OC) is a multifaceted relationship of indirect and direct pathophysiological factors connected to obesity. Obesity is an autonomous risk factor for coronary artery disease (CAD) and is robustly linked with diabetes mellitus (DM) and hypertension, which circuitously lead to the development of

* Corresponding author S. Sengottuvelu: Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, 638052, India; E-mail: sehejan@gmail.com

hypertensive, ischemic and cardiomyopathy correspondingly [1]. There are definite structural changes related to OC and body weight and heart weight display a linear bond. Particularly, left ventricular remodelling with augmented wall width and mass, as well as ventricular dilatation are well-established consequences of obesity, even after controlling for age and hypertension [2]. Extreme fatty acids may direct prejudiced myocardial presentation due to the gathering of toxic long-chain non-esterified fatty acids and their by-products such as ceramides and diacylglycerols. This state is referred to as lipotoxic heart disease [3]. Insulin resistance (IR), one of many obesity-associated metabolic derangements, may also arbitrate the progress of cardiomyopathy through mutilation of myocardial oxygen utilization, myocardial fatty acid uptake and oxidation. Prominent myocardial triglyceride levels may also alter myocardial function and structure [4].

On the other hand, elevated oxidative stress in the cardiomyocytes arises through numerous mechanisms, including mitochondrial uncoupling and dysfunction, increased fatty acid oxidation, superior NADPH oxidase activity, and abridged antioxidant capacity [5]. It has been documented that obesity may persuade systemic oxidative stress. Biomarkers of oxidative stress are elevated in patients with obesity and correlate in a straight line with body mass index and the proportion of body fat; on the contrary, an opposite association between central adiposity, body fat and antioxidant capacity has been recommended. A number of processes are concerned with obesity-related oxidative stress, caused by a high intake of fat and carbohydrate meals [6, 7]. These observations point out that the modulation of oxidative stress by antioxidants appears to have an optimistic outcome in the avoidance of OC.

Several attempts have been made to spot the metabolic inconsistency of obesity state, producing a number of drugs like sibutramine, fibrates and orlistat, but they experience from substantial side effects [8]. Therapeutical approaches to obesity devoid of any side effects are still a dispute in the medical system of human beings. There is a mounting demand by individuals to use natural products with antiobesity nature because oral antiobesity drugs have numerous side effects [9]. In the same way, Zingiberene (ZB) is a monocyclic sesquiterpene that is the principal constituent of *Zingiber officinale* and in addition, previous reports indicated that ZB has various therapeutic effects [10]. On the other hand, there was no scientific evidence available on the antiobesity activity of ZB in animal models or any other clinical models. Therefore, the current study intended to find out the therapeutic efficacy of ZB against high-fat diet (HFD)-induced obesity and OC in rats.

2. MATERIALS AND METHODS

2.1. Chemicals

ZB was purchased from Sigma-Aldrich, India.

2.2. Animals

We procured male Wistar rats (weighing 120-140g) from the Nandha College of Pharmacy, Erode, Tamilnadu, India and rats were initially acclimatized for the period of one week with a 12 h day/night cycle, in a temperature of $22 \pm 2^\circ\text{C}$, and humidity of 45-64%. The protocol of this study was approved by the Institutional Animal Ethical Committee (IAEC), Nandha College of Pharmacy (Approval No: 688/PO/Re/S/02/CPCSEA).

2.3. HFD Composition

HFD was commercially obtained (National Institute of Nutrition, Hyderabad, India) and composed of corn starch (15%), sugar (27.5%), lard oil (17.6%), vitamin mixture (1%), mineral mixture (3.5%), casein (20%), cellulose powder (5%), corn oil (9.9%) and choline bitartrate (0.2%).

2.4. Experimental Design

Obesity was induced by the supplementation of HFD for the period of 15 weeks and treatment with respective drugs was initiated. At the same time, normal control rats were fed with a normal pellet diet. The rats were divided into four groups and each group contained six animals. All the respective drugs were administered orally by using intragastric tube for the period of 45 days once a day.

Group 1: Normal control

Group 2: HFD-induced obese control

Group 3: Obese + ZB (50mg/kg body weight)

Group 4: Obese + Lorcaserin (10mg/kg body weight)

At the end of the 45 days treatment period with respective drugs, all the rats were overnight fasted and blood was collected by retro orbital sinus puncture method with mild anaesthesia. Then, the rats were sacrificed by the cervical decapitation and vital organs were collected immediately and stored at -80°C until further use.

Betaine, a Nutraceutical Ameliorated Myocardial Infarction by Attenuation of Pro-Inflammatory Cytokines and Matrix Metalloproteinase Production in Rats

G. Somasundaram^{1,*}, S. Jaikumar¹ and S. Sengottuvelu²

¹ Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502, India

² Department of Pharmacology, Nandha College of Pharmacy, Erode, Tamilnadu, 638052, India

Abstract: Cardiovascular disease is a key community health challenge and presently the condition with the utmost deaths around the globe, even though enormous development has been made in its management but there are still many difficulties. In the current study, we made an attempt to evaluate the therapeutic action of betaine, an active nutraceutical against isoproterenol-induced myocardial infarction (MI) in rats. The rats were pre-treated with betaine (250mg/Kg BW) for the period of 30 days and on the 31st and 32nd days, they were administered with isoproterenol (20mg/Kg BW) to produce MI in rats. Then we evaluated the effects of betaine on the ratio of heart weight to the body weight. Cardiac diagnostic markers and the production of pro-inflammatory cytokines and matrix metalloproteinases along with their mRNA expressions were also studied in the heart by RT-PCR. We found that there was a significant elevation in the heart size, levels of LDH, CK-MB, CRP, homocysteine and serum pro-inflammatory cytokines (TNF- α , IL-1 α , IL-1 β , IL-6, MCP-1 and RANTES) and matrix metalloproteinases (MMP-2 and MMP-9) in MI rats. On the other hand, pre-treatment of MI rats with betaine revealed a noteworthy reduction in the pro-inflammatory cytokines and matrix metalloproteinases in the serum. RT-PCR study revealed that betaine successfully down-regulated the mRNA expressions of NF- κ B, TNF- α , IL-6, MMP-2 and MMP-9 in MI rats. In conclusion, this study revealed that betaine is able to ameliorate MI by restraining the production of pro-inflammatory cytokines and matrix metalloproteinases. Hence, betaine might be used as a dietary supplement as an alternative for cardio-protection.

Keywords: Betaine, Cardiovascular disease, Myocardial infarction, Natural products, Nutraceuticals.

* **Corresponding author G. Somasundaram:** Department of Pharmacology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry, 605502-India; E-mail: umeshkumar82@gmail.com

Dr. V. V. Sathibabu Uddand Rao & Dr. Parim Brahma Naidu (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

1. INTRODUCTION

Cardiovascular disease (CVD) is the main reason for morbidity and mortality both in developing and urbanized countries. A foremost form of CVD is myocardial infarction (MI), which usually comes across as a quiet infarction due to its late diagnosis in the disease development. When the equilibrium between the blood supply to the heart vessels and the necessity of the cardiac tissue is affected, the cardiomyocytes are subjected to a long-lasting ischemic damage ensuing in necrosis, frequently well-known as acute MI [1]. In recent decades, with changes in the way of life and predilection to co-morbidities, the frequency of MI has been found in the adolescent to be mounting with age in the middle and elder age groups, affecting both women and men [2]. The condensed blood supply to the heart results in the deficiency of oxygen to cardiac muscles, which if left untreated, results in permanent necrotic harm to the myocardium. In most cases, the cardiac arrest is sudden with no noticeable symptoms of ache and a severe impulsivity [3].

MI is an extremely multifaceted disorder with multistep progression in which numerous physiological systems contribute. Wide-ranging investigational data exposed that MI is intricately connected with the commencement of an inflammatory reaction [4]. Inflammatory mediators are openly implicated in the pathogenesis of the susceptible plaque, foremost to occlusion of the coronary vessel and consequent necrosis of the myocardial region served by the vessel [5]. Scientific studies have identified critical molecular signals mediating the inflammatory response following MI. Therapeutic interventions in experimental animal models recommended that the balanced reserve of particular inflammatory signals may protect the infarcted heart from acute damage and delay unwanted remodelling following MI [6]. On the other hand, matrix metalloproteases (MMPs) play a vital role in post-MI cardiac remodelling and in the increase of unpleasant outcomes. MMPs synchronize key life activities, along with inflammation and development. The changes in MMPs may direct to unwanted circumstances, resulting in the progress of a variety of possible complications, including sudden cardiac arrest, left ventricular rupture, or the increase of congestive heart failure. The potential roles of MMPs as a therapeutic target for MI setting, thus, are warranted. Simultaneously, lots of currently used medications to treat MI encourage MMPs activity. Identifying specific MMPs inhibition approaches for the post-MI patient; predominantly treatments that limit the development of heart failure, remains a greatly needed target [7].

For acute conditions, such as MI, modern drugs have been alleged as the only available therapeutic approach. On the other hand, an understanding pertaining to conventional medicine for MI has been rising. Therapeutic plants have been

mostly used for healthcare around the globe even before the arrival of modern medicine [8], and the consumption of diets rich in plant foods is connected with an abridged CVD risk [9, 10]. Betaine is circulated widely in plants, animals and rich dietary sources which include seafood, spinach and wheat bran [11]. Betaine has several therapeutic effects which include antioxidants [12], antiobesity, antidiabetic [13] and hepatoprotective [14]. However, the protective effect of betaine on myocardial inflammation and the MMP system in experimentally induced MI conditions has not yet been previously explored. Hence, the current study was designed to evaluate the effect of betaine on pro-inflammatory cytokines and MMPs production in isoproterenol (ISO)-induced MI in rats.

2. MATERIALS AND METHODS

Betaine ($((\text{CH}_3)_3\text{N}^+\text{CH}_2\text{COO}^-)$) and ISO were purchased from the Sigma-Aldrich, India.

2.1. Animals

The Wistar rats (weighing 120-140g) were utilized for this study and obtained from the Nandha College of Pharmacy, Erode, Tamilnadu, India. The animals were maintained at a 12 h day/night cycle, at a temperature of $22 \pm 2^\circ\text{C}$, and humidity of 45-64%. The protocol of this study was approved by the Institutional Animal Ethical Committee, Nandha College of Pharmacy (Approval No: 688/PO/Re/S/02/CPCSEA).

2.2. Experimental Design

Group 1: Normal control

Group 2: ISO-induced MI untreated control

Group 3: Rats were pre-treated with betaine (250mg/kg BW) orally for 30 days and ISO (20mg/kg BW) administered once a day subcutaneously on the 31st and 32nd days.

Group 4: Rats were pre-treated with α -tocopherol (60mg/kg BW) orally for 30 days and ISO (20mg/kg BW) administered once a day subcutaneously on the 31st and 32nd days.

SUBJECT INDEX

A

- Abdomen 113
 bloated 113
 Abdominal obesity 4, 126
 Abnormal glucose tolerance 58
 Absorption 7, 11, 34, 141
 intestinal 34
 Acid(s) 6, 8, 13, 14, 15, 16, 39, 46, 82, 84,
 133, 135, 136, 137, 142, 145, 167, 174,
 177, 180, 181
 acetylsalicylic 8
 alpha-linolenic (ALA) 13
 amino 6, 84
 arachidonic 14
 arjunolic 137
 ascorbic 15
 betulinic 167
 docosahexaenoic 13
 eicosapentaenoic 13
 folic 39
 free fatty (FFAs) 174, 177, 180, 181
 galloannic 145
 glutamic 84
 gymnemic 137
 hydroxycitric 135
 lactic 13
 linoleic 142
 nicotinic 133
 nucleic 82
 oleanolic 145
 oleic 16, 142
 palmitic 142
 petroselinic 142
 phenolic 135, 136
 thiobarbituric 46
 ursolic 167
 Acquired coronary heart diseases 89
 Actions 6, 7, 14, 116, 138, 139, 186, 195
 aldosterone-secreting 6
 anti-atherogenic 116
 anticlotting 138
 cardiac 7
 electrical 7
 inhibitory 139
 lipid-lowering 14
 therapeutic 186, 195
 Activities 31, 65, 104, 107, 112, 137, 138,
 139, 140, 142, 143, 165, 172, 194
 anthelmintic 142
 anticancer 139
 antihypercholesterolemic 143
 antihyperlipidemic 142
 antihypertensive 137
 anti-inflammatory 194
 antiobesity 172
 cardiac cell 31
 distorted 112
 glucocorticoid 165
 hypocholesterolemic 140
 metabolic 65, 138
 paracrine 104, 107
 superior NADPH oxidase 172
 Adam stroke syndrome 115
 Adaptive immune responses 43
 Adeno-associated virus (AAVs) 67, 91, 94
 Adipocytes 43, 142, 146
 mature 43
 Adipogenesis 146
 Aldosterone 166
Allium Sativum 12, 143
 Alzheimer's disease 40
 Amalgamations 90
 Ameliorate 171, 197
 Amplification reaction 160
 Anaemia 30, 131
 Anaesthesia 69, 158
 Angina 2, 10, 116, 130, 134, 137
 pectoris 137
 Angiogenesis 196
 Angiography 69
 Angiotensin-converting enzyme (ACE) 29,
 133, 166
 inhibitors 29

- Anthocyanidins 135
Anthocyanins 14, 16, 135, 136, 139
Anthocynins 136
Anthropometrical index 180
Antiarrhythmics 6, 13, 129, 137
Anti-atherogenesis 147
Antiatherogenic agent 55
Anti-atherosclerotic effects 136
Anti-coagulants drugs 8
Anti-dyslipidemia 147
Anti-flatulent properties 145
Anti-hypercholesterolemic effects 45
Anti-inflammatory 11, 16, 39, 42, 43, 45
 action 16
 agents 11, 42, 43, 45
 effects 39
Antinuclear antibodies 131
Antioxidant(s) 11, 12, 13, 14, 16, 38, 45, 46,
 115, 118, 135, 136, 137, 138, 140, 142,
 143, 145, 147, 148, 181, 182
 activities 118, 136, 137
 capacity, non-enzymatic 46
 effects 11, 13
 endogenous 115
 enzymes 16, 138, 181, 182
 polyphenolic 12
 properties 13, 14, 118
 response 16
Antioxidant system 171, 182
 cardiac 182
Antioxidant vitamins 15, 18
 food-containing 18
Aortic constriction 52, 61, 71, 72
Apolipoprotein 17, 54, 55, 56, 88, 128
Apoprotein 54
Apoptosis 60, 88, 106, 115, 197
 myocardial 60, 197
Apoptotic process 88
Appendicitis 133
Applications, translational 52
Arrhythmias 10, 12, 13, 33, 52, 90, 91, 108,
 114, 116, 130, 131, 132
 cardiac 33, 52
Arrhythmogenic right ventricular
cardiomyopathy (ARVC) 27
Arteriosclerosis 128
Arthritis 45, 138
Atherogenesis 9, 42, 54, 55, 181
 vascular bed 9
Atherogenesis lesions 56
Atherosclerosis 2, 4, 5, 9, 42, 52, 53, 54, 55,
 56, 66, 67, 126, 127, 128, 129, 144
 aortic 67
 coronary 66
 lesions 9
 risk of 9, 129
Atherosclerotic 9, 54, 55, 56, 66, 67
 aortic 54
 lesions 54, 55, 56, 66, 67
Atherothrombosis 8
ATPase 31, 33, 34
 enzyme 31
ATPase pump 33
 sodium-potassium 33
Atrial 3, 25, 26, 30, 31, 34, 35, 115
 arrhythmia 31
 fibrillation 3, 25, 26, 30, 34, 35, 115
Autosomal disease 87
- ## B
- Bacteria 14, 82, 87
 health-promoting 14
Bacterial plasmids 82
Beta-adrenergic blocking 30
 agents 30
 drugs 30
Bioactive peptides 10, 14
BioAssay systems 174
Bioinformatics 2, 17
 application 17
 approach 2
Biological phenotypes 95
Biomarkers 2, 172
 novel therapeutic 2
 of oxidative stress 172
Blood 11, 15, 54, 57, 67, 106, 107, 108, 113,
 128, 129, 130, 132, 133, 134, 158, 176
 disorders 129, 130, 132
 glucose 57, 176
 lipids 15
Blood pressure 6, 8, 12, 13, 71, 115, 134, 137,
 138, 139, 156, 157, 158, 159
 diastolic 71, 159
 reduction 13
 systolic 71, 158
Body 172, 174, 175, 179, 180
 lipid 180
 mass index (BMI) 172, 174, 175, 179
Brachial neuralgia 117

- Bradycardia 72
Bronchospasm 131
Bufodienolide poisoning 33
- C**
- Calcium 33, 41, 42, 139, 146
 channels, voltage-dependent 139
 release 33
Cancer 2, 11, 14, 15, 40, 42, 44, 45, 46, 80,
 82, 87, 88, 141, 144
 human cervical 88
 surpassed 2
Capsicum annum 146
Carbohydrate(s) 10, 39, 40, 41, 42, 134, 138,
 140, 141, 143, 144, 145, 172
 diet 10
 high glycemic index 39
 meals 172
 refined 41
 restricting high glycemic index 41
Cardiac 2, 14, 27, 34, 52, 60, 61, 63, 64, 89,
 91, 105, 107, 114, 115, 180, 181, 187,
 189, 190, 191, 194, 195, 196, 197
 arrest 64, 187
 computed tomography 2
 diseases 27, 52, 89, 91
 events 114
 fibroblast 197
 fibrosis 60, 61, 181
 function responses 63
 functions 14, 34, 107, 115, 180, 196
 ischemia 61
 magnetic resonance imaging 2
 membrane 195
 MRI 114
 mRNA expressions 194
 muscle dysfunction 181
 toxicity 63
 troponin 189, 190, 191, 195, 196
Cardiac glycoside(s) 25, 31, 32, 33, 34, 35,
 134, 140
 biotransformation 34
 containing plants 34
Cardiac hypertrophy 52, 60, 167
 pathological 167
Cardiac lipid 174, 177, 178
 peroxidation 178
 profile 174, 177
Cardiac lipotoxicity 171, 182
 ameliorated 171
Cardiomyocytes 12, 89, 90, 91, 115, 172, 187,
 196, 197
 infect 91
 necrotic 91, 196
Cardio-myopathic complication 71
Cardiomyopathy 2, 27, 79, 90
 hypertrophic 2, 27, 90
 inherited 79
 restrictive 27
Cardioprotective 12, 134, 135, 137, 146, 194,
 195
 activities 137, 146, 195
 effect 194, 195
Cardiotoxins 62
Cardiovascular diseases 18, 41, 131, 136
 developing 41
 prevention of 41, 131
 risk of 18, 41, 136
Cardiovascular 9, 38, 39, 53, 132
 diseases research 53
 events 9, 132
 inflammation 38, 39
Carminative agent 46
Carnitine 13
 content reductionis 13
Carolina medical electronics 159
Carotenoids 15, 16, 134, 135, 136
 lycopene antioxidant 16
Catalase 46, 174
Catastrophic health 4
 costs 4
 spending 4
Catechins 14, 15, 16, 136, 142
Cell 11, 93, 116, 180, 195, 196
 cycle arrest 11
 energy metabolism 180
 infiltration 195, 196
 metabolism 116
 penetrating peptides 93
Cellular adhesion 27
Cerebrovascular 2, 9, 126
 disease 2, 126
 events 9
Chemistry of cardiac glycosides 31
Chest 34, 62, 113, 127
 incision 62
 radiograph 34
Chinese 13, 45
 medicine 45

- plant *optischinensis* 13
- Cholecystokinin 58
- Cholesterol 4, 5, 9, 11, 13, 14, 15, 41, 42, 54, 55, 56, 60, 64, 66, 127, 133, 147, 181
 - deposition 5
 - developed elevated plasma 56
 - diet 60, 66
 - efflux 147
 - high-density lipoprotein 127
 - ingested 11
 - lowering medications 133
 - synthesis 13, 15, 181
- Cholesterol absorption 11, 133, 182
 - inhibitors 133
- Cholinergic-mediated vascular effects 139
- Chow diet 55
- Chronic 31, 46, 56, 70, 71, 87, 136
 - congestive heart failure 70
 - dialysis 46
 - diseases 136
 - granulomatous disorders (CGD) 87
 - obstructive pulmonary disease (COPD) 31, 56
 - valvular disease 71
- Chronic inflammations 42, 43, 87
 - disease 42
- Cinnamaldehyde 142
- Cinnamon 142, 143, 147
 - polyphenols 143
- CIRSPR technology 92
- Cleaves plasminogen 9
- Clogging 108, 138
 - preventing 138
- CMD prognosis 105, 106, 119
- Collagen redeployment 197
- Combination therapy 157
- Computed tomography (CT) 2
- Concomitant reduction 181
- Conditions 7, 26, 27, 29, 35, 40, 42, 52, 53, 67, 70, 83, 87, 138, 182, 186, 195
 - atherosclerotic 42
 - cardiac 7, 195
 - rheumatological 138
- Congestive heart failure (CHF) 10, 12, 25, 26, 27, 29, 31, 33, 34, 35, 64, 70, 181
- Consumption 4, 14, 26, 41, 45, 125, 137, 181, 188
 - excessive alcohol 4, 26
- Contractile dysfunctions 108, 115
- Contractility 108, 115, 181
 - cardiac 108
 - myocardial 115
- Contraction 7, 8, 25, 29, 33, 107, 115, 116
 - cardiac myocyte 8
 - force 29
 - myocardial 25, 115
- Control 16, 40, 41, 134, 158, 161, 162, 163, 164, 165, 166, 167, 168, 175, 176, 177, 178, 179, 192, 193
 - anti-oxidative 16
 - blood pressure 41
 - glycemic 134
 - hypertensive 158, 161, 162, 163, 164, 165
 - lifelong weight 40
- Coriandrum sativum* 141
- Corn starch 173
- Coronary 2, 9, 11, 13, 14, 26, 52, 53, 62, 64, 67, 68, 89, 90, 91, 113, 138, 144, 146, 171
 - artery disease (CAD) 2, 26, 52, 138, 171
 - disease 90
 - heart disease (CHD) 9, 11, 13, 14, 26, 53, 89, 90, 91, 144, 146
 - occlusion 62
 - vasculature 64
- Creatine 114, 189
 - kinase-MB isoenzyme 189
 - Phospho-Kinase-MB (CPKMB) 114
- CRISPR 79, 80, 81, 82, 83, 84, 85, 86, 88, 89, 92, 93, 94, 95, 96
 - gene technology 89
 - method 85
 - nickase enzyme 94
 - system 81, 86, 88
 - techniques 84, 85, 86
 - technologies 79, 80, 81, 82, 83, 84, 86, 92, 93, 94, 95, 96
- Crocus sativus* 135
- Cryptoxanthin 141
- Curcuma longa* 139
- Curcumin 12, 136, 140
- Curcuminoids 46
- CVD 2, 4, 9, 43, 126, 147, 195
 - diagnosis 4, 195
 - disorders 9
 - morbidity 126
 - mortality 2, 4
 - promoting conditions 43
 - protection 147
 - related deaths 2

- risk 9
- Cyclic adenosine monophosphate 14
- Cystic-fibrosis transmembrane 84
- Cytokines 43, 44, 45, 55, 118, 189, 196
 - inflammatory 43, 44, 118, 189, 196
 - proatherogenic 43
 - proinflammatory 196
- D**
- Damage 12, 29, 45, 82, 119, 128, 157, 181, 182, 195
 - cardiac 195
 - cardiovascular 181
 - endothelial 157
 - free radical induced tissue cell 182
 - polyunsaturated LDL 12
 - tissue 45, 181
- Deaths 2, 3, 4, 11, 52, 53, 79, 87, 90, 126, 179, 186
 - proportionate 4
- Defective phagocytes 87
- Dehydrated garlic 143
- Demands 61, 105, 107
 - metabolic 105, 107
 - perfusion 61
- Demerits 89, 95
 - heart lopping 89
- Dendritic cells 140
- Densitometric analysis 160
- Deposition 12, 42, 113, 127, 179
 - atheromatous 12
- Detoxification genes 16
- Dexamethasone 156, 157
 - exposure 156
- Diabetes mellitus (DM) 4, 56, 59, 66, 114, 132, 143, 171, 180
- Diabetic nephropathy 129, 130
- Diacylglycerol signalling 180
- Diastolic blood pressure (DBP) 71, 157, 159, 162, 163
- Diet 38, 39, 40, 44, 45, 55, 67
 - atherogenic 55
 - high-cholesterol 55, 67
 - ketogenic 40, 44
 - low carbohydrate 38, 40, 45
 - low-cholesterol 67
 - pro-inflammotry 39
- Dietary 39, 60, 137
 - foods 137
 - inflammation 39
 - Inflammatory Index (DII) 39
 - manipulation 60
- Diet-associated inflammation 39
- Diet induced 38, 56
 - inflammation 38
 - steatohepatitis 56
- Digitoxigenin 34
- Digoxin medication 34
- Dihydrocoriandrin 142
- Dihydrodigoxin 34
- Disease(s) 1, 2, 42, 43, 45, 46, 53, 54, 55, 56, 71, 80, 88, 90, 96, 112, 114, 117, 129, 157
 - communicable 129
 - etiology 96
 - metabolic 157
 - pathogenesis 53
 - prognosis 112, 117
 - skin 117
- Disorders 4, 30, 44, 53, 54, 80, 81, 84, 86, 87, 91, 105, 108, 116, 117, 126, 137, 142, 144, 145, 181, 187
 - alcohol use 30
 - allergic 145
 - autoimmune 44
 - cardiac 91
 - hereditary dyslipidemic 54
 - metabolic 105, 108, 116, 137, 181
 - multifaceted 187
 - multifactorial 87
 - neurodegenerative 44
 - stomach 142
- Dizziness 127, 129, 130, 131, 132
- DNA 16, 80, 81, 82, 88, 93, 94, 95, 96, 167
 - binding transcription factors 167
 - cleavage 93, 96
 - exogenous 80, 82
 - splicing protein 96
 - target locus 81
- Doppler echocardiography 62
- Double-strand breaks (DSB) 81, 82, 90, 96
- Drugs 7, 25, 31, 54, 56, 60, 62, 64, 66, 68, 72, 91, 129, 130, 134, 172
 - anti-arrhythmia 91
 - anti-diabetic 60
 - atherosclerotic 54
 - cytotoxic 62
 - hypolipidemic 56
 - immune-suppressive 72

oral antiobesity 172
Duchenne muscle dystrophy (DMD) 71, 86
Dysfunction 5, 26, 29, 127, 131, 132, 133,
157, 166, 172
diastolic 26
endothelial 5, 127, 166
hepatic 131, 132
myocardial 29
renal 157
sexual 133
Dyslipidemia 4, 9, 40, 43, 56, 57, 58, 125,
126, 127, 146, 171, 180
diabetic 56, 57
pro-atherogenic 43
Dyspepsia 131, 133
Dyspnea 25, 26, 30, 31, 34
Dyspnoea 132

E

Echocardiography 116
Edema 9, 30, 108, 117
acute pulmonary 9
Effective nutraceuticals 138
Effect(s) 11, 141, 144, 146, 147, 156, 172,
178, 188, 194, 195,
antihyperlipidemic 141
antihypertensive 156
atheroprotective 147
cardiac 195
hallucinogenic 146
of betaine on cardiac mRNA expressions
194
of ZB on cardiac lipid peroxidation 178
on nutraceuticals on cardiovascular health
11
therapeutic 144, 172, 188
Efficacy 12, 29, 54, 57, 63, 68, 95, 118, 125,
139, 157, 182, 196
antihypertensive 157
anti-inflammatory 196
anti-obesity 182
therapeutic 125, 139
Electrocardiograms 2, 90, 114
Electrophysiology 64
Elettaria cardamomum 146
ELISA method 189
Emboli coil implantation 70
Emerging CRISPR Technologies 95

Endocarditis 4
Endogenous retrovirus 92
Endothelial 13, 15, 16, 42, 115, 137
functions 13, 15, 16, 115, 137
integrity 42
Energy 25, 26, 34, 115, 117, 118, 180
balance 180
condensed 180
depletion 115
metabolism 118
storage 180
Engineered mega nucleases 81
Enzymatic proteolysis 6
Enzyme 8, 13, 93, 114, 133, 141, 181, 195
cardiac 114
cytosolic 195
gastro-intestinal 141
mitochondrial 181
reverse transcriptase 93
Epicatechins 136, 142
Equilibrium 106, 111, 112, 119, 187
body's thermal 106
Erectile dysfunctions 56, 117
Escherichia coli 82
Euvolemic hyponatremia 30
Exercise tolerance 25, 29, 34
Expression 15, 18, 79, 84, 85, 107, 108, 111,
115, 156, 164, 167, 168
down-regulated mRNA 164
genetic 79
phenotypic 85

F

Factors 2, 5, 15, 30, 38, 39, 52, 53, 80, 96,
105, 110, 111, 112, 114, 115, 117, 118,
157, 181
dietary 2
endothelium-derived hyperpolarizing 157
endothelium-derived relaxing 115
environmental 53, 80
etiological 112, 117
genetic 5
hepatic transcription 15
tumor necrosis 114, 118
Fagonia Arabica 118
Failure 26, 30, 33, 55, 69, 70, 195, 196
cardiac 26, 33, 69, 196
myocardial infarction/heart 70
Fatal disease 61

- Fat(s) 39, 40, 41, 42, 54, 55, 56, 113, 172, 179
hydrogenated 39
milk 55
soluble lubrication 113
- Fatty acid(s) 1, 10, 13, 15, 17, 18, 39, 40, 43, 146, 148, 172
polyunsaturated 18, 148
bsynthase 17
toxic long-chain non-esterified 172
unsaturated 39, 40
- Fever 114, 131, 142
seasonal 142
- Fiber 1, 15, 18, 38, 41, 90, 143
dietary 1, 18
smooth muscle 90
- Fibroblasts, fetal 68
- Fibrosis 29, 60, 61, 71, 80, 82, 83, 110, 113, 115, 167, 195, 196
cystic 80, 82, 83
myocardial 115
- Ficus hispida* 135
- Flavonoids 2, 12, 14, 134, 135, 136, 138, 140, 142, 144, 145
- Flow 104, 106, 108, 110, 113, 115, 133
oscillatory 115
- Food and drug administration (FDA) 30, 34, 134
- Foods 1, 10, 12, 18, 34, 40, 106, 111, 112, 118, 141, 144, 146, 179
excessive 179
healthy fats-rich 40
swallowing 106
therapeutic 1
- Free radical scavenging 147
- Fruits 12, 14, 15, 39, 40, 41, 134, 135, 136, 137, 142
citrus 136
low-glycemic 41
- Functions 6, 12, 13, 26, 61, 79, 84, 85, 89, 91, 104, 105, 106, 108, 109, 113, 119, 172, 180, 181
cardiovascular 61
cognitive 85
compromised 105
contractile 104, 105, 119
explicit gene 79
myocardial 172
neuroendocrine 26
- Gallate 135, 136
epicatechin 136
- Garcinia indica* 135
- Garlic 1, 12, 18, 143, 144, 147
therapeutic effects of 144
- Gastritis 132
- Gene(s) 6, 12, 13, 16, 17, 18, 57, 67, 71, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 94, 95, 96, 119, 129, 156, 164, 166, 167, 189, 190, 196
adeno-associated virus-mediated 67
alterations 95
allele-dominant 85
cytoprotective 16
delivery 91
duplication 6
dystrophin 71, 86
expression 12, 13, 88, 119, 156, 164, 167
housekeeping 189
hub 18
hunting 85
induced 80
leptin 57
leptin-receptor 57
lipoprotein 129
multi-factorial 96
mutations 67, 86, 91
proinflammatory-associated 196
therapy 79, 81, 91
therapy tools 81
- Generations 12, 80, 93, 94
mitochondrial energy 12
- Genesis 31, 104, 115
abnormal 115
- Genetic(s) 41, 42, 54, 61, 79, 80, 81, 85, 86, 90, 128
alleles 86
diseases 80
disorders 80
modifying human 81
mutations 80
tool kits 85
- Genome editing 82, 83, 84
natural 83
tools 83
- Genome-wide association studies (GWAS) 90
- Genomic 16, 96
databases 96
processes 16

G

- Glucose 14, 39, 40, 113, 143, 174, 180, 195
dysregulated 180
intake 39
tolerance test (GTT) 113
- Glucose uptake 142, 180
insulin-mediated 180
- Glucosinolates 146
- Glutathione 46, 174, 178, 179, 181, 182
peroxidase 46, 174
reductase (GR) 174, 178, 179, 181, 182
- Glycosides 14, 32, 33, 134, 135, 138, 141
cardiotonic 33
flavonoid 14
steroid 32
- Glycosuria 57, 59
- Glycyrrhiza glabra* 137
- Growth 4, 89, 140, 179
economic 4
suppress tumor 140
- GSH protein 182
- Guanylyl cyclase 139
- H**
- Haemophilia 82
- Haemorrhage 131, 132
intestinal 131
- Haemorrhagic strokes 3
- HDL cholesterol levels 136, 137
- Headache 129, 130, 131, 132, 133, 138
- Health 45, 104
disorders 45
restoring 104
- Healthy eating index 39
- Heart 2, 6, 7, 8, 25, 26, 27, 33, 34, 35, 60, 89, 105, 106, 107, 108, 115, 119, 126, 134, 144, 171, 178, 181, 187
attacks 2, 8, 26, 126, 144
contraction 33, 34
infarcted 187
lipid peroxidation 181
metabolism 181
tonics 34
transplantation 27, 35
- Heart diseases 2, 3, 12, 14, 26, 53, 63, 70, 71, 89, 116, 126, 172
adult congenital 26
congenital 89, 126
hypertensive 3, 12
ischaemic 70
ischemic 3, 12, 116
lipotoxic 172
rheumatic 2, 3, 53
- Heart failure 26, 29, 30, 31, 61, 62, 72,
nonischemic 29, 30
stable chronic 72
stimulus 61
symptoms 26, 31
syndromes 62
- Heart muscle 7, 14, 29, 107, 195
contractions 29
fibres 195
- Hemodynamic forces 108
- Hemoglobin 84, 85, 114
glycosylated 114
- Hemophilia 86
- Hemostasis 113
- Hepatic 34, 130, 146
biotransformation 34
encephalopathy 130
steatosis 146
- Hepatoprotective 135, 145, 188
- Herbaceous perennial plant 146
- High-cholesterol content 54
- High density lipoprotein (HDL) 9, 67, 127
- High-fat-diet 171
- High reproductive efficiency 58
- High-risk papillomavirus 88
- Histone deacetylases 156, 160
- HMG CoA reductase inhibitors 9
- Homeostasis 84, 107, 113, 166, 180
deregulated energy 180
electrolytic 84
kidney 166
- Homocysteine 15, 61, 186, 189, 190, 191, 195
lowering blood 15
- Homogenates 160, 174
aortic 160
- Homologous mending processes 87
- Homology-directed repair (HDR) 81, 82, 83, 90, 93, 94
- Human 56, 57
obesity 57
vasculopathy 56
- Huntington's 80, 85
disease 80, 85
protein 85
- Hydronephrosis 58
- Hypercholesterolemia 54, 58, 67
- Hyperglycemia 58, 146, 148, 180

Hyperinsulinemia 56, 57, 58, 59, 180
Hyperleptinemia 60
Hyperlipidaemias 133
Hyperlipidemia 2, 10, 57, 58, 127, 148
Hyperphagia 59
Hyperplasia 58, 195
 fibroblastic 195
Hypertension 2, 4, 12, 13, 14, 57, 125, 129,
 130, 131, 132, 137, 156, 157, 158
 sensitive 157
Hyperthyroidism 131
Hypertriglyceridemia 13, 56, 59
Hypertrophic cardiomyopathy (HCM) 2, 27,
 90
Hypertrophy 12, 16, 27, 58, 60, 61, 113, 195
 adipocyte 58
 myocardial 195
Hyponatremia 30
Hypotension 129, 130, 132

I

Illnesses 12, 18, 26, 88
 cardiac 12
 cardiovascular 18
 monogenetic 88
 thyroid 26
Immune 14, 47
 boosting properties 47
 function 14
Immunoboosting 148
Immunological deficiencies 87
Impaired glucose tolerance (IGT) 57, 59
Impairment 25, 26, 59, 107, 108, 116, 118,
 126, 129
 cognitive 25, 26
 gestational metabolic 59
 renal 129
Induction of hypertension 158, 167
Infarction 4, 7, 8, 60, 64, 69, 72, 131, 186
 acute myocardial 4, 7, 60, 64, 131
 chronic myocardial 72
 developing Myocardial 69
 isoproterenol-induced myocardial 186
Infections 26, 82, 87, 132, 136
 pathogenic 136
 urinary tract 132
Inflammation 39, 43, 44, 45, 55, 56, 59, 111,
 113, 127, 128, 188, 195, 196
 myocardial 188

Inflammatory 13, 91, 137, 187, 196
 enzyme COX-2 13
 processes 137
 reaction 91, 187, 196
Inhibitors 6, 29, 92, 133
 angiotensin-converting enzyme 6, 29
 angiotensin receptor-nepirylsin 133
 lipoprotein lipase 92
Injury 8, 11, 29, 114, 116, 118, 196
 cardiac 29
 constant reperfusion 196
 ischemia reperfusion 11
 myocardial 114, 116, 118
Insulin 143, 174, 176, 180
 sensitivity 180
Intermediate-density lipoprotein (IDL) 54,
 128
Ischemia 8, 36, 60, 113, 136, 195
 myocardial 136
Ischemic heart disease (IHD) 3, 12, 29, 116

K

Ketosis 40
Kidney disease 41

L

Lactate dehydrogenase 189
Lagenaria siceraria 135
Left ventricular 25, 26, 27
 ejection fraction (LVEF) 25, 26
 noncompaction (LVNC) 27
Lentivirus-mediated CRISPR technologies 94
Leptin 56, 57
 hormone 57
 mutation 57
Leucoanthocyanin 140
Lipid 14, 60, 61, 64, 116, 147, 174, 177, 178,
 179, 180, 181, 182
 homeostasis 116
 peroxidation 147, 174, 178, 181, 182
 profile 14, 64, 147, 177, 179, 180
 rich occlusion 60, 61
Lipid metabolism 52, 53, 56, 108, 180
 cardiac 180
Lipoproteins 9, 17, 54, 55
 high density 9
 lipase 17

- Low-density lipoprotein(s) (LDL) 4, 5, 11, 12, 13, 46, 54, 67, 88, 127, 128, 129, 147
cholesterol 88
oxidized 46
- Lowering 9, 18
blood lipids 18
LDL cholesterol 9
- M**
- Macronutrients 39, 43
eating 43
- Macrophages 13, 44, 55, 137, 140, 196
pro-inflammatory 44
- Malfunction 167
- Malignant tendencies 88
- MAPKs activation 147
- Matrix 186, 187
metalloproteases 186
metalloproteases 187
- Mechanical cell deformations 93
- Mechanism 6, 7, 8, 9, 15, 29, 31, 33, 45, 47, 79, 82, 83, 84, 93, 112, 137, 165, 196
anti-inflammatory 45
cholesterol-lowering 15
homology-directed repair 83
immunological 82
of action of amiodarone 7
of action of amlodipine 8
of action of aspirin 8
of action of candesartan 6
of action of lidocaine 7
of action of procainamide 7
of action of trandolapril 6
of action of urokinase 9
of cardiac glycosides 33
protein refolding 84
thermoregulatory 112
- Mediators, inflammatory 39, 44, 66, 187
- Medications 6, 7, 8, 9, 34, 117, 118, 187
anti-arrhythmic 7
cardiac 8
herbal 9
- Medicines 6, 7, 8, 9, 10, 18, 33, 45, 79, 96, 139, 142, 144
antiarrhythmic 7
antithrombotic 9
genomic 96
traditional 139
- Mediterranean dietary index 39
- Metabolic 2, 18, 38, 43, 46, 53, 105, 114, 116, 126, 130
alkalosis 130
program 18
syndrome 2, 38, 43, 46, 53
syndrome disorders 126
system (MS) 105, 114, 116
- Metabolism 14, 17, 25, 54, 64, 137
cardiac 54, 64, 137
lipoprotein 54, 137
- Metabolites 6, 17, 106, 119, 195
pathologic 195
- Methods 17, 55, 62, 79, 84, 87, 93, 159, 190
ANOVA 190
enzymatic conversion 159
gene therapy 87
gene therapy treatment 79
homologous recombination 84
hydrodynamic delivery 93
imaging 55
lucigenin-enhanced chemiluminescence 159
reductionist 17
surgical 62
transduction 93
- Microdeposits 131
- Microembolisation 70
- Microflora, intestinal 14
- Micronutrients 39, 134
- Milk 18, 146, 160
protein peptides 18
skimmed 160
- Mineralocorticoid effects 166
- Minneapolis 189
- Monocyclic sesquiterpene 171, 172
- Monogenic diseases 82
- Morbidities 42, 53, 107, 110, 117, 125, 187
cardiovascular 42
- Moringa oleifera* 134, 146
- Mucuna pruriens* 135
- Multifactorial diseases 82, 87
- Multiple 15, 60, 83
diffuse lipid-rich stenosis 60
organ dysfunctions 83
sclerosis 15
- Muscle cells 7, 8, 14, 33, 91, 115, 157, 196
cardiac 7, 14, 33, 91
smooth 91
vascular smooth 8, 115, 157, 196
- Muscle contraction 7, 8
smooth 8

Muscle(s) 6, 8, 13, 14, 31, 62, 71, 107, 108, 109, 112, 116, 119, 139, 187
cardiac 8, 14, 107, 187
metabolism 116
progressive 71
respiratory 31
vascular smooth 6, 8, 139
Mutations, transcriptase-introduced 93
Myeloperoxidase 46
Myocardial 4, 5, 8, 13, 25, 26, 62, 68, 70, 72, 79, 116, 186, 187, 195, 196, 197
infarction (MI) 4, 5, 8, 13, 25, 26, 68, 70, 72, 79, 186, 187, 195, 196, 197
ischemia-induced heart failure 62
stiffness 116
Myocardial damage 181, 196
ischemic 196
Myocarditis 26
Myocytes 8, 13, 7, 33, 104, 115
cardiac 8, 13
Myofibroblasts 196
Myosin filaments 29
Myristica fragrans 146
Myristicin 146

N

NADPH oxidase 167
Nausea 132, 133, 142
Necrosis 106, 111, 115, 131, 187, 195
Neomycin resistance gene 68
Nephropathy 128
Neprilysin 133
Nerium oleander plant 32
Neurohormonal 26, 29, 31
dysregulation 31
systems 29
Neuropathy 58, 131
peripheral 131
Neurotransmission 116
Neutrophil(s) 140, 197
degranulation 197
Nitric oxide metabolites 159
Non-alcoholic fatty liver disease 44
Non-communicable disease (NCDs) 3, 52, 129
Nonenzymatic anti-oxidant systems 15
Non-homologous end joining (NHEJ) 81, 82, 91, 94
Noninvasive tail-cuff plethysmography 158

Nourishing metabolite 107
Nuclear acetylation 12
Numerous surgical methods 62
Nutraceuticals modulate genetic expression 16
Nutrient utilization 180

O

Obesity 43, 44, 56, 57, 58, 114, 116, 125, 157, 171, 172, 173, 174, 176, 179, 180, 181, 182
ameliorate 182
associated metabolic derangements 172
cardiomyopathy (OC) 157, 171, 172, 179, 181, 182
index 174, 176, 179
Occlusion 8, 60, 69, 70, 187
temporary 70
vascular 8
Oil(s) 11, 13, 16, 40, 41, 134, 138, 140, 142, 143, 144, 145, 173
canola 13
corn 173
essential 138, 140, 142, 145
olive 16, 40, 41
seeds 40
vegetable 11, 13
Olea europaea 135
Oral supplementation 162, 164
Organ failure 115
Osmocytosis 94
Oxidation 12, 13, 15, 16, 172, 181
reducing 13
Oxidative 12, 16, 45
burst 45
damage 12, 16
Oxidative stress 16, 45, 59, 115, 171, 172, 178, 179, 180, 181, 182
obesity-related 172
systemic 172
vanished 182

P

Pain 25, 26, 31, 109, 113, 127, 131, 132, 133
abdominal 131, 133
Palpitations 114, 130
Pancreas 58, 59, 66, 83
offspring 59

- Pancreatitis 132, 133
- Pathogenesis 25, 42, 44, 57, 89, 96, 106, 112, 113, 116, 181, 187
- diabetic 44
 - related issues 96
- Pathological dryness 111, 112, 113
- promoting 111, 112
- Pathologic thirst 113
- Pathophysiology, diabetic 57
- Pathways 16, 17, 62, 81, 82, 139, 157, 196
- disease progress 81
 - renin angiotensin 157
 - vasodilator 139
- Periodontal disease 58
- Peripheral 2, 4, 52, 116
- arterial disease 2
 - vascular disease 4, 52, 116
- Peroxisome-proliferator-activated receptors (PPARs) 17
- Peroxynitrite inactivation 12
- Phenotype 55, 56, 119
- plasma lipoprotein 56
- Phenotypic constitution 111
- Phenylpropanoids 146
- Phospholipids 174
- Phytochemicals 10, 11, 15, 134, 136, 137, 138, 144, 145, 148
- Mahanimbine 145
- Phyto-pharmacological interventions of
- antioxidants 114
- Phytosterols 11, 140
- Piper nigrum* 140, 141
- Plant(s) 1, 11, 18, 31, 32, 134, 136, 138, 142, 143, 148, 188, 194, 197
- and herbs 134, 148
 - derived phytoconstituents 194
 - sterols 1, 11
- Plaque 8, 12, 43, 53, 54, 55, 128
- aortic 55
 - atheromatous 43
 - atherosclerotic 8, 12, 128
- Plaque 60, 66
- haemorrhage 66
 - stenosis 60
- Plasma 54, 55, 88, 158, 167, 180, 197
- insulin 180
 - lipoprotein profile 54
- Plasma glucose 180
- augmented 180
- Plasmid-based delivery systems 94
- Platelet aggregation 8, 13, 16, 18, 136, 137, 147
- inhibiting 8
 - preventing 18
- Platelet-derived growth factor (PDGF) 12
- Pneumonitis 131
- Polydipsia 58, 59, 113
- Polyphenolic anti-oxidants 141
- Polyvinylidene difluoride membrane 160
- Predisposition, genetic 67
- Pressure 26, 62, 64
- pulmonary capillary wedge 26
 - systolic 64
- Preventive cardiology 104
- Problems 3, 81, 92, 93, 125
- biomedical 81
 - global health 125
- Production 8, 12, 13, 17, 85, 89, 94, 159, 162, 163, 164, 166, 180, 181, 186, 192
- hepatic glucose 180
 - inflammatory markers 192
 - lipid 17
 - malondialdehyde 181
 - mitochondrial 12
- Prognosis 2, 27, 52, 64, 104, 105, 118, 196
- Programming 59, 166
- epigenetic 59
- Progression 5, 42, 43, 54, 58, 71
- atherosclerotic plaque 43
- Pro-inflammatory 39, 43, 186, 188, 196
- cytokines 186, 188, 196
 - effects 39
 - lipoproteins 43
- Properties 12, 33, 68, 105, 111, 115, 118, 119, 137, 138, 139, 142, 143, 148, 181
- amphiphilic 181
 - anti-apoptotic 12
 - antiatherosclerotic 148
 - anti-oxidant 105
 - biomechanical 68
 - cardio-suppressant 139
 - intrinsic 105, 111, 119
 - intrinsic oxidant 115
 - metal chelating 137
 - thrombolytic 118
 - triacylglycerols lipase 142
- Prostaglandins 8, 9, 13
- pain-inducing 8
- Protease 9, 55, 197
- active fibrinolytic 9

secretion 55
serine 9
Protein(s) 14, 15, 16, 38, 40, 41, 42, 82, 84,
86, 93, 119, 138, 141, 143, 146, 160,
164, 165, 167, 180
biosynthesis 180
dystrophin 86
expressions 119, 165, 167
fusion 93
inhibitory 16
lupin 14
regulatory element binding 15
Proteomics 119
Psidium guajava 135
Pulmonary 2, 89
atresia 89
embolism 2
Pumps 33, 105
calcium ions 33
sodium-potassium 33
Purpura, thrombocytopenic 131

R

Reactive oxygen species (ROS) 11, 42, 87,
136, 182
Recovery, myocardial 72
Reduction of hyperlipidemia and
hyperglycemia 148
Regulation 15, 88, 91, 93, 164, 167, 180
metabolic 91
Regulatory mechanisms, genetic 89
Rehabilitation 31
breathlessness 31
Research, translational 52, 71
Respiratory cycle 181
Response, inflammatory 187, 196
Restrictive cardiomyopathy (RCM) 27
Reteplase 9
Retinopathy 128
Reverse 93, 119, 189
transcription 93
Rheumatic heart disease (RHD) 2, 3, 53
Right ventricular diastolic pressure 65
Risk 1, 4, 5, 9, 10, 11, 12, 13, 18, 40, 41, 42,
134, 136
cardiovascular 5, 9, 134
chronic disease 40
socioeconomic 18

Risk factors 1, 4, 5, 9, 43, 125, 127, 128, 143,
171, 179, 180, 181
autonomous 171
cardiovascular 1, 4
for cardiovascular diseases 5
RNA 81, 82
target-oriented 81
trans-activating 82
RT-PCR Analysis 159, 189, 196

S

Secoiridoids 135
Sensitivity 25, 26
therapeutic 26
Sheath 69
arterial vascular 69
Sickle cell 80, 84
anemia 80, 84
disease 84
Signaling pathways 16, 116, 118
inhibitory 118
Skin 62, 65, 69, 131, 137
discoloration 131
incision 62, 69
Sleep disturbances 130
Somatic cell 67, 93
gene-editing 93
Source 12, 32, 65, 66, 85, 91
of cardiac glycosides 32
SPSS software 161
Staphylococcus aureus 92
Stem cells 72, 79, 89
human mesenchymal 72
induced pluripotent 79, 89
Stenosis 64, 113
aortic 64
Stents 63, 66, 68
drug-eluting 66
Streptokinase 118
Steroids 135, 138, 139, 140, 141, 144, 145
Strategy 133, 137
combinatorial treatment 133
Streptokinase 9
Stress 111, 179, 180
lipid profiles and oxidative 179, 180
Stroke 2, 4, 8, 9, 52, 126, 128, 137, 146
ischemic 8
Super oxide dismutase (SOD) 46, 115, 174,
178, 179, 181, 182

- Supra-ventricular arrhythmias 131
- Surgeries 71, 72
cardiac 72
cardiovascular 71, 72
- Surplus glucocorticoids 165
- Syndrome 40, 91, 114, 118, 130, 131, 132
acute coronary 118, 132
cardiac 91
polycystic ovary 40
respiratory distress 131
- Synthesis 9, 118, 142, 159, 165, 166, 196
glycogen 142
- Synthetic glucocorticoid 165
- System 29, 35, 84, 105, 119, 127, 157, 181
antioxidant defence 181
dysfunctional endothelial 127
gastrointestinal 35
metabolic 105
musculoskeletal 119
organoid 84
renin-angiotensin 29
sympathetic nervous 157
- Systolic 26, 27, 30, 71, 158, 159, 162, 163, 166
blood pressure (SBP) 71, 158, 159, 162, 163, 166
dysfunction 26, 30
function 27
- T**
- Techniques 63, 68, 81, 82, 83, 89, 93, 114, 119
gene-editing 89
genome-editing 81
homology-based base-pairing 83
imaging 63, 114
- Technology 66, 80, 81, 92
emerging 66
gene editing 80
genome-editing 92
target gene-editing 81
technology-based editing 92
- Terpene hydrocarbons 146
- Thalassemia 80, 82, 85
- Therapeutic activity 139, 142, 143, 145
of cinnamon 143
of cloves 145
of coriander 142
- Therapeutic(s) 18, 79, 83, 88, 95, 187
molecule RNA 79
plants 187
targets 18, 187
tools 83, 88, 95
- Therapies 6, 9, 18, 25, 31, 33, 35, 84, 88, 117
device 35
- Thermoregulation 111, 112, 113
- Thrombocytopenia 131
- Thrombolytic treatment 8
- Thrombosis 2, 126
vein 2
- Thrombotic events 132
- Thyroid disease 30
- Tissues 6, 8, 25, 26, 32, 44, 59, 61, 93, 108, 111, 112, 113, 119, 164, 167, 195
aortic 164, 167
cardiac nodal 8
damaged 195
insulin target 59
interstitial 111
mammalian 32
matured adipose 44
metabolizing 108, 112, 119
myocardial 61
visceral adipose 44
- TNF-sensitive regulatory factor 90
- Transcription activator-like effector nucleases (TALENs) 80, 81, 84, 96
- Transcription factors 16, 17, 81, 167
octamer-binding 81
- Transcriptomics approach 17
- Transferring vehicles 91
- Transmyocardial implantation 72
- Transplantations 72, 92
intramyocardial 72
- Transport, metabolite 106, 115
- Transporter 12, 89
electron 12
- U**
- Urokinase 9, 118
- V**
- Valvular 26, 89
heart disease (VHD) 26, 89
- Vascular 38, 55, 104, 137, 156, 159
diseases 104

- dysfunction 156
- inflammation 38
- lumen morphology 55
- reactivity 137
- resistance 159
- Vasoactive agents 166
- Vasoconstriction 108, 112, 113, 115, 166
 - induced systemic 166
- Vasoconstrictors 9, 157
 - inflamed tissue-derived 157
- Vasodilation 9, 108, 115, 139
 - mediated 139
- Vasodilators 133, 134, 139, 157
 - endothelium-independent 139
- Vasopressin receptor antagonists 25, 30
- Vasopressor ionotropes 30
- Vata disorders 112
- Vectors 68, 91, 92, 94
 - adenovirus 91
 - defective lentiviral 92
 - viral-based 94
- Very-low-density lipoprotein (VLDL) 54, 129, 146, 147
- Viral vector systems 94
- Vomiting 127, 131, 132, 133

W

- World health organization 41

X

- Xeno transplantations 92
- X-linked 86, 87
 - degenerative disease 86
 - genetic illness 86
 - granulomatous disease 87

Z

- Zinc-finger nucleases (ZFNs) 80, 81
- Zingiber Officinale* 138, 171, 172
- Zucker 58
 - diabetic fatty (ZDF) 58
 - fatty rat for hyperglycemia 58



V. V. Sathibabu Uddandrao

Dr. V. V. Sathibabu Uddandrao is currently working as an Assistant Professor of Biochemistry at K.S. Rangasamy College of Arts and Science (Autonomous), Tiruchengode, Tamilnadu, India. He received his Ph.D. degree from Periyar University, Tamilnadu, India. He has received a junior research fellowship from a DST-SERB-funded project and has also been awarded a senior research fellowship (ICMR-SRF) from the Indian Council of Medical Research (ICMR), Government of India. He is currently working on metabolic disorders (Diabetes, Obesity, Cardiovascular disorders) and nutraceuticals. He has published 40 research articles in reputed international peer-reviewed journals with high impact factors and 2 book chapters in standard book editions, published by international publishers. He received the “National Level Best Academic Researcher” award in the year 2019 from Dr. Kalam Educational Trust, Tamilnadu. He is also currently acting as an author and reviewer and editing a few books.



Parim Brahma Naidu

Dr. Parim Brahma Naidu is currently working as DST-Inspire faculty in ICMR- National Animal Resource Facility for Biomedical Research, Hyderabad, India. He received M.Sc., and Ph.D., degrees from Periyar University, Tamilnadu, India and Jawaharlal Nehru Technological University Hyderabad (JNTUH), Hyderabad, India, respectively. He did a PG diploma in patent law from Nalsar University, Hyderabad, India and underwent lab animal supervisor training from ICMR-National Institute of Nutrition (NIN), Hyderabad, India. He is an expert in cardiovascular disorders, obesity and its treatment with natural products. He has received funded projects from the DST-INSPIRE, Government of India. He has published 31 research articles and 4 review articles in reputed international journals. He also published 5 book chapters in standard book editions. He is currently serving as a reviewer and editing a few books.